<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1110211117
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Trivira
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EFAVIRENZ,TENOFOVIR DISOPROXIL,EMTRICITABINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        600,300,200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2404.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; III" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – III
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AR06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Efavirenz, Emtricitabine and Tenofovir Disporoxil Fumarate Tablets that are used to treat human immunodeficiency virus (HIV) infection:</p><p>-&nbsp; Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI)</p><p>-&nbsp; Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI)</p><p>-&nbsp; Tenofovir is a nucleotide reverse transcriptase inhibitor (NtRTI)</p><p>Each of these active substances, also known as antiretroviral medicines, work by interfering with an enzyme (reverse transcriptase) that is essential for the virus to multiply.</p><p><strong>Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets is a treatment for Human Immunodeficiency Virus </strong>(HIV) infection in adults aged 18 years and over who have previously been treated with other antiretroviral medicines and have their HIV-1 infection under control for at least three months. Patients must not have experienced failure of a previous HIV therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets</strong></p><p>-&nbsp; if you are allergic to Efavirenz, Emtricitabine, tenofovir, tenofovir disoproxil or any of the other ingredients of this medicine (listed in section 6).</p><p>-&nbsp; if you have severe liver disease.</p><p>-&nbsp; if you have a heart condition, such as an abnormal electrical signal called prolongation of the QT interval that puts you at high risk for severe heart rhythm problems (Torsade de Pointes).</p><p>-&nbsp; if any member of your family (parents, grandparents, brothers or sisters) has died suddenly due to a heart problem or was born with heart problems.</p><p>if your doctor has told you that you have high or low levels of electrolytes such as potassium or magnesium in your blood.</p><p>-&nbsp;&nbsp; <strong>if you are currently taking </strong>any of the following medicines (see also &ldquo;Other Medicines and Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets &rdquo;):</p><p>-&nbsp; <strong>astemizole or terfenadine </strong>(used to treat hay fever or other allergies)</p><p>-&nbsp; <strong>bepridil </strong>(used to treat heart disease)</p><p>-&nbsp; <strong>cisapride </strong>(used to treat heartburn)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ergot&nbsp;&nbsp;&nbsp;&nbsp; alkaloids&nbsp;&nbsp;&nbsp;&nbsp; </strong>(for&nbsp;&nbsp;&nbsp;&nbsp; example,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ergotamine,&nbsp;&nbsp;&nbsp;dihydroergotamine,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ergonovine, and methylergonovine) (used to treat migraines and cluster headaches)</p><p>-&nbsp; <strong>midazolam or triazolam </strong>(used to help you sleep)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <strong>pimozide, imipramine, amitriptyline or clomipramine </strong>(used to treat certain mental conditions)</p><p>-&nbsp; <strong>St. John&rsquo;s wort </strong>(<em>Hypericum perforatum</em>) (a herbal preparation used for depression and anxiety)</p><p>-&nbsp; <strong>voriconazole </strong>(used to treat fungal infections)</p><p>-&nbsp; <strong>flecainide, metoprolol </strong>(used to treat irregular heart beat)</p><p>-&nbsp; <strong>certain antibiotics </strong>(macrolides, fluoroquinolones, imidazole)</p><p>-&nbsp; triazole antifungal agents</p><p>&nbsp;</p><p>-&nbsp; <strong>certain antimalarial agents</strong></p><p>-&nbsp; <strong>methadone </strong>(used to treat opiate addiction)</p><p>&middot;&nbsp;&nbsp; <strong>If you are taking any of these medicines, tell your doctor immediately. </strong>Taking these medicines with Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets&nbsp; could cause serious or life-threatening side effects or stop these medicines from working properly.</p><p>Warnings and precautions</p><p>Talk to your doctor or pharmacist before taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.</p><p>-&nbsp; <strong>You can still pass on HIV </strong>when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your doctor the precautions needed to avoid infecting other people. This medicine is not a cure for HIV infection. While taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets you may still develop infections or other illnesses associated with HIV infection.</p><p>-&nbsp;&nbsp; You must remain under the care of your doctor while taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.</p><p>-&nbsp; Tell your doctor:</p><p>-&nbsp; <strong>if you are taking other medicines </strong>that contain efavirenz, emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or lamivudine or adefovir dipivoxil. Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets should not be taken with any of these medicines.</p><p>-&nbsp; <strong>if you have or have had kidney disease, </strong>or if tests have shown problems with your kidneys. Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets is not recommended if you have moderate to severe kidney disease</p><p>Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets may affect your kidneys. Before starting treatment, your doctor may order blood tests to assess kidney function. Your doctor may also order blood tests during treatment to monitor your kidneys.</p><p>Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets is not usually taken with other medicines that can damage your kidneys (see <em>Other medicines and Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets </em>). If this is unavoidable, your doctor will monitor your kidney function once a week.</p><p>&nbsp;</p><p>-&nbsp; if you have a heart disorder, such as abnormal electrical signal called prolongation of the QT interval.</p><p>-&nbsp; <strong>if you have a history of mental illness, </strong>including depression, or of substance or alcohol abuse. Tell your doctor immediately if you feel depressed, have suicidal thoughts or have strange thoughts (see section 4, <em>Possible side effects</em>).</p><p>-&nbsp;&nbsp; <strong>if you have a history of convulsions (fits or seizures) </strong>or if you are being treated with anticonvulsant therapy such as carbamazepine, phenobarbital and phenytoin. If you are taking any of these medicines, your doctor may need to check the level of anticonvulsant medicine in your blood to ensure that it is not affected while taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets . Your doctor may give you a different anticonvulsant.</p><p>-&nbsp; <strong>if you have a history of liver disease, including chronic active hepatitis. </strong>Patients with liver disease including chronic hepatitis B or C, who are treated with combination antiretrovirals,&nbsp; have a higher risk of severe and potentially life-threatening liver problems. Your doctor may conduct blood tests in order to check how well your liver is working or may switch you to another medicine. <strong>If you have severe liver disease, do not take Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets </strong>(see earlier in section 2, <em>Do not take Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets ).</em></p><p>If you have hepatitis B infection, your doctor will carefully consider the best treatment regimen for you. Tenofovir disoproxil and emtricitabine, two of the active substances in Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , show some activity against hepatitis B virus although emtricitabine is not approved for the treatment of hepatitis B infection. Symptoms of your hepatitis may become worse after discontinuation of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets . Your doctor may then conduct blood tests at regular intervals in order to check how well your liver is working (see section 3, <em>If you stop taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets ).</em></p><p>-&nbsp; Independent of a history of liver disease, your doctor will consider regular blood tests to check how your liver is working.</p><p>-&nbsp; <strong>if you are over 65. </strong>Insufficient numbers of patients over 65 years of age have been studied. If you are over 65 years of age and are prescribed Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , your doctor will monitor you carefully.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; Once you start taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , look out for:</p><p>-&nbsp;&nbsp; <strong>signs of dizziness, difficulty sleeping, drowsiness, difficulty concentrating or abnormal dreaming. </strong>These side effects may start in the first 1 or 2 days of treatment and usually go away after the first 2 to 4 weeks.</p><p>-&nbsp;&nbsp; <strong>any signs of skin rash. </strong>Rashes may be caused by Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets . If you see any signs of a severe rash with blistering or fever, stop taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets and tell your doctor at once. If you had a rash while taking another NNRTI, you may be at higher risk of getting a rash with Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets .</p><p>-&nbsp;&nbsp; <strong>any signs of inflammation or infection. </strong>In some patients with advanced HIV infection (AIDS) and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to improvement in the body&rsquo;s immune response, enabling the body to fight infections that may have been present with no obvious symptoms. If you notice any symptoms of infection, please tell your doctor at once</p><p>In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.</p><p>-&nbsp; <strong>bone problems</strong>. Some patients taking combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). The length of combination antiretroviral therapy, corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index, among others, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are joint stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement. If you notice any of these symptoms please inform your doctor.</p><p>&nbsp;</p><p>Bone problems (sometimes resulting in fractures) may also occur due to damage to kidney tubule cells (see section 4, <em>Possible side effects</em>).</p><p>Children and adolescents</p><p>-&nbsp;&nbsp; <strong>Do not give Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets to children and adolescents </strong>under 18 years of age. The use of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in children and adolescents has not been studied.</p><p><strong>Other medicines and Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets You must not take Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets with certain medicines. </strong>These are listed under <em>Do not take Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , </em>at the start of section 2. They include some common medicines and some herbal preparations (including St. John&rsquo;s wort) which can cause serious interactions.</p><p><strong>Tell your doctor </strong>or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Also, Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets should not be taken with any other medicines that contain efavirenz (unless recommended by your doctor), emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or lamivudine or adefovir dipivoxil.</p><p><strong>Tell your doctor </strong>if you are taking other medicines which may damage your kidneys. Some examples include:</p><p>-&nbsp; aminoglycosides, vancomycin (medicines for bacterial infections)</p><p>-&nbsp; foscarnet, ganciclovir, cidofovir (medicines for viral infections)</p><p>-&nbsp; amphotericin B, pentamidine (medicines for fungal infections)</p><p>-&nbsp; interleukin-2 (to treat cancer)</p><p>-&nbsp; non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)</p><p>Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets may interact with other medicines, including herbal preparations such as Ginkgo biloba extracts. As a result, the amounts of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets or other medicines in your blood may be affected. This may stop your medicines from working properly, or may make any side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels. <strong>It is important to tell your doctor or pharmacist if you are taking any of the following:</strong></p><p>&nbsp;</p><p>-&nbsp; <strong>Medicines containing didanosine (for HIV infection): </strong>Taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets with other antiviral medicines that contain didanosine can raise the levels of didanosine in your blood and may reduce CD4 cell counts. Inflammation of the pancreas and lactic acidosis (excess lactic acid in the blood), which sometimes caused death, have been reported rarely when medicines containing tenofovir disoproxil and didanosine were taken together. Your doctor will carefully consider whether to treat you with medicines containing tenofovir and didanosine.</p><p>-&nbsp;&nbsp; <strong>Other medicines used for HIV infection: </strong>The following protease inhibitors: darunavir, indinavir, lopinavir/ritonavir, ritonavir, or ritonavir boosted atazanavir or saquinavir. Your doctor may consider giving you an alternative medicine or changing the dose of the protease inhibitors. Also, tell your doctor if you are taking maraviroc.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Medicines used to treat infection with the hepatitis C virus: </strong>boceprevir, simeprevir, sofosbuvir/velpatasvir, sofosbuvir/velpatasvir/voxilaprevir.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Medicines used to lower blood fats (also called statins): </strong>Atorvastatin, pravastatin, simvastatin. Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets can reduce the amount of statins in your blood. Your doctor will check your cholesterol levels and will consider changing the dose of your statin, if needed.</p><p>-&nbsp; <strong>Medicines used to treat convulsions/seizures (anticonvulsants): </strong>Carbamazepine, phenytoin, phenobarbital. Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets can reduce the amount of the anticonvulsant in your blood. Carbamazepine can reduce the amount of efavirenz, one of the components of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , in your blood. Your doctor may need to consider giving you a different anticonvulsant.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Medicines used to treat bacterial infections, </strong>including tuberculosis and AIDS-related mycobacterium avium complex: Clarithromycin, rifabutin, rifampicin. Your doctor may need to consider changing your dose or giving you an alternative antibiotic. In addition, your doctor may consider giving you an additional dose of efavirenz to treat your HIV infection.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Medicines used to treat fungal infections (antifungals): </strong>Itraconazole or posaconazole. Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets can reduce the amount of itraconazole or posaconazole in your blood. Your doctor may need to consider giving you a different antifungal.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; <strong>Medicines used to treat malaria: </strong>Atovaquone/proguanil or artemether/lumefantrine. Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets may reduce the amount of atovaquone/proguanil or artemether/lumefantrine in your blood.</p><p>-&nbsp;&nbsp;&nbsp; <strong>Hormonal contraceptive, such as birth control pills, an injected contraceptive (for example, Depo-Provera), or a contraceptive implant (for example, Implanon): </strong>You must also use a reliable barrier method of contraception (see <em>Pregnancy and breast-feeding</em>). Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets may make hormonal contraceptives less likely to work. Pregnancies have occurred in women taking efavirenz, a component of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , while using a contraceptive implant, although it has not been established that the efavirenz therapy caused the contraceptive to fail.</p><p>-&nbsp; <strong>Sertraline, </strong>a medicine used to treat depression, as your doctor may need to change your dose of sertraline.</p><p>-&nbsp; <strong>Bupropion</strong>, a medicine used to treat depression or to help you stop smoking, as your doctor may need to change your dose of bupropion.</p><p>-&nbsp;&nbsp; <strong>Diltiazem or similar medicines (called calcium channel blockers): </strong>When you start taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , your doctor may need to adjust your dose of the calcium channel blocker.</p><p>-&nbsp; <strong>Medicines used to prevent organ transplant rejection (also called immunosuppressants)</strong>, such as cyclosporine, sirolimus or tacrolimus. When you start or stop taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets your doctor will closely monitor your plasma levels of the immunosuppressant and may need to adjust its dose.</p><p><strong>- Warfarin or acenocoumarol </strong>(medicines used to reduce clotting of the blood): Your doctor may need to adjust your dose of warfarin or acenocoumarol.</p><p>- <strong>Ginkgo biloba extracts </strong>(herbal preparation).</p><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Women should not get pregnant during treatment with Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets and for 12 weeks thereafter. Your doctor may</p><p>&nbsp;</p><p>require you to take a pregnancy test to ensure you are not pregnant before starting treatment with Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.</p><p><strong>If you could get pregnant while receiving Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, </strong>you need to use a reliable form of barrier contraception (for example, a condom) with other methods of contraception including oral (pill) or other hormonal contraceptives (for example, implants, injection). Efavirenz, one of the active components of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , may remain in your blood for a time after therapy is stopped. Therefore, you should continue to use contraceptive measures, as above, for 12 weeks after you stop taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets .</p><p><strong>Tell your doctor immediately if you are pregnant or intend to become pregnant. </strong>If you are pregnant, you should take Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets only if you and your doctor decide it is clearly needed.</p><p>Serious birth defects have been seen in unborn animals and in the babies of women treated with Efavirenz during pregnancy.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>If you have taken Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.</p><p><strong>Do not breast-feed during treatment with Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets. </strong>Both HIV and the ingredients of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets may pass through breast milk and cause serious harm to your baby.</p><p>Driving and using machines</p><p><strong>Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets may cause dizziness, impaired concentration and drowsiness. </strong>If you are affected, do not drive and do not use any tools or machines.</p><p>Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets contains sodium</p><p>This medicine contains 1 mmol (23.6 mg) of sodium per tablet which should be taken into consideration if you are on a controlled sodium diet.</p><p>&nbsp;</p><p>Driving and using machines</p><p>Tenofovir Disporoxil Fumarate Tablets can cause dizziness. If you feel dizzy while taking Tenofovir Disporoxil Fumarate Tablets, <strong>do not drive or ride a bicycle </strong>and do not use any tools or machines..</p><p>Tell your doctor before taking Tenofovir Disporoxil Fumarate Tablets if you cannot tolerate lactose or if you have intolerance to any other sugars.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is:</p><p>One tablet taken each day by mouth. Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets should be taken on an empty stomach (commonly defined as 1 hour before or 2 hours&nbsp; after a meal) preferably at bedtime. This may make some side effects (for example, dizziness, drowsiness) less troublesome. Swallow Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets whole with water.</p><p>Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets must be taken every day.</p><p>If your doctor decides to stop one of the components of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets , you may be given efavirenz, emtricitabine and/or tenofovir disoproxil separately or with other medicines for the treatment of your HIV infection.</p><p>If you take more Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets&nbsp; than you should</p><p>If you accidentally take too many Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets tablets you may be at increased risk of experiencing possible side effects with this medicine (see section 4, <em>Possible side effects</em>). Contact your doctor or nearest emergency department for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.</p><p>If you forget to take Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets</p><p>It is important not to miss a dose of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets .</p><p>&nbsp;</p><p><strong>If you do miss a dose of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets within 12 hours of when it is usually taken</strong>, take it as soon as you can, and then take your next dose at its regular time.</p><p><strong>If it is almost time (less than 12 hours) for your next dose </strong>anyway, do not take the missed dose. Wait and take the next dose at the regular time. Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you throw up the tablet (within 1 hour after taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets )</strong>, you should take another tablet. Do not wait until your next dose is due. You do not need to take another tablet if you were sick more than 1 hour after taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets</p><p><strong>If you stop taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets Don&rsquo;t stop taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets without talking to your doctor. </strong>Stopping Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets can seriously affect your response to future treatment. If Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets is stopped, speak to your doctor before you restart taking Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets . Your doctor may consider giving you the components of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets separately if you are having problems or need your dose adjusted.</p><p><strong>When your supply of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets starts to run low, </strong>get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The virus may then become harder to treat.</p><p><strong>If you have both HIV infection and hepatitis B, </strong>it is especially important not to stop your Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets treatment without talking to your doctor first. Some patients have had blood tests or symptoms indicating that their hepatitis has got worse after stopping emtricitabine or tenofovir disoproxil (two of the three components of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets ). If Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets is stopped your doctor may recommend that you resume hepatitis B treatment. You may require blood tests to check how your liver is working for 4 months after stopping treatment. In some patients with advanced liver disease or cirrhosis,</p><p>stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.</p><p>&nbsp;Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible serious side effects: tell your doctor immediately</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>- Lactic acidosis </strong>(excess lactic acid in the blood) is a <strong>rare </strong>(may affect up to 1 in every 1,000 patients) but serious side effect that can be fatal. The following side effects may be signs of lactic acidosis:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - deep rapid breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - feeling sick (nausea), being sick (vomiting) and stomach pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you think you may have lactic acidosis, contact your doctor immediately. Other possible serious side effects</p><p>The following side effects are <strong>uncommon </strong>(these may affect up to 1 in every 100 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction (hypersensitivity) that may cause severe skin reactions (Stevens-Johnson syndrome, erythema multiforme, see section 2)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angry behaviour, suicidal thoughts, strange thoughts, paranoia, unable to think clearly, mood being affected, seeing or hearing things that are not really there (hallucinations), suicide attempts, personality change (psychosis), catatonia (a condition in which the patient is rendered motionless and speechless for a period).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in the abdomen (stomach), caused by inflammation of the pancreas</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; forgetfulness, confusion, fitting (seizures), incoherent speech, tremor (shaking)</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellow skin or eyes, itching, or pain in the abdomen (stomach) caused by inflammation of the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to kidney tubules</p><p>Psychiatric side effects in addition to those listed above include delusions (false beliefs), neurosis. Some patients have committed suicide. These problems tend to occur more often in those who have a history of mental illness. Always notify your doctor immediately if you have these symptoms.</p><p>Side effects to the liver: If you are also infected with hepatitis B virus, you may experience a worsening of hepatitis after discontinuation of treatment (see section 3).</p><p>The following side effects are rare (these may affect up to 1 in every 1,000 patients):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure, in some cases leading to death or liver transplant. Most cases occurred in patients who already had liver disease, but there have been a few reports in patients without any existing liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidney, passing a lot of urine and feeling thirsty</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain caused by kidney problems, including kidney failure. Your doctor may do blood tests to see if your kidneys are working properly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; softening of the bones (with bone pain and sometimes resulting in fractures) which may occur due to damage to the kidney tubule cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fatty liver</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you think that you may have any of these serious side effects, talk to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Most frequent side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following side effects are <strong>very common </strong>(these may affect more than 1 in 10 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, headache, diarrhoea, feeling sick (nausea), being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak</p><p><em>Tests may also show:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreases in phosphate levels in the blood</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased levels of creatine kinase in the blood that may result in muscle pain and weakness</p><p>Other possible side effects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following side effects are <strong>common </strong>(these may affect up to 1 in 10 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbances of coordination and balance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling worried or depressed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping, abnormal dreams, difficulty concentrating, drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with digestion resulting in discomfort after meals, feeling bloated, wind (flatulence)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in skin colour including darkening of the skin in patches often starting on hands and soles of feet</p><p><em>Tests may also show:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood cell count (a reduced white blood cell count can make you more prone to infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver and pancreas problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased fatty acids (triglycerides), bilirubin or sugar levels in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following side effects are <strong>uncommon </strong>(these may affect up to 1 in every 100 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of muscle, muscle pain or weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia (low red blood cell count)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of spinning or tilting (vertigo), whistling, ringing or other persistent noise in the ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast enlargement in males</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased sexual drive</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased appetite</p><p><em>Tests may also show:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreases in potassium in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increases in creatinine in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; proteins in urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased cholesterol in the blood</p><p>The breakdown of muscle, softening of the bones (with bone pain and sometimes resulting in fractures), muscle pain, muscle weakness and decreases in potassium or phosphate in the blood may occur due to damage to kidney tubule cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following side effects are <strong>rare </strong>(these may affect up to 1 in every 1,000 patients)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy rash to the skin caused by a reaction to sunlight</p><p>&nbsp;</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:88.2pt;margin-top:19.45pt;width:382.65pt;height:124.75pt;
  z-index:-251650048;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:67.1pt;margin-bottom:
     0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:150%'>The
     National Pharmacovigilance and Drug Safety Centre (NPC) o Fax:
     +966-11-205-7662<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt'>o Call NPC at
     +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.6pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l2 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.1pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Toll free phone:<span style='letter-spacing:-.1pt'> </span>8002490000<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.95pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l2 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.1pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>E-mail: <a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:blue;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.85pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l2 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='letter-spacing:-.1pt'><span style='mso-list:Ignore'>o<span
     style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
     dir=LTR></span>Website:<span style='letter-spacing:-.05pt'> </span><a
     href="http://www.sfda.gov.sa/npc"><span style='color:blue;text-decoration:
     none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp; Toll free phone: 8002490000</p><p>o&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp; Website: www.sfda.gov.sa/npc</p><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Efavirenz, Emtricitabine and Tenofovir disporoxil Fumarate Tablets contains </strong>The active substance is Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 600mg/200mg/300mg.</p><p>Each film coated tablet contains 600 mg of Efavirenz USP, 200 mg of Emtricitabine USP and 300 mg of Tenofovir disoproxil fumarate, equivalent to 245 rng of Tenofovir disoproxil.</p><p>The other ingredients are:, microcrystalline cellulose, Pregelatinized starch, Croscarmellose sodium, Hydroxy propyl cellulose Sodium lauryl sulfate, Magnesium Stearate Opadry II Pink 85F94172, Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pink coloured, capsule shaped, film coated tablets debossed with ‘H’ on one side and ‘128’ on the other side..
How supplied:
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 600mg/200mg/300mg - container 30’s count HDPE Container.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ترايفيرا أقراص على المواد الفعالة ايفافرنيز ، امتريسيتابين و تينوفوفير ديسوبروكسيل فيوميرات والتي تنتمي إلى مجموعة دوائية تسمى مضادات الفيروسات ، ويستخدم لعلاج عدوى فيروس نقص المناعة البشري .</p><p dir="RTL">ايفافرنيز هو مثبط لأنزيم النســخ&nbsp;العكســـي الغير نيوكليوتيدي ، والمعروف عمومًا باسم NNRTI</p><p dir="RTL">امتريسيتابين هو مثبط لأنزيم النســخ&nbsp;العكســـي للنوكليوتيد ، والمعروف عمومًا باسم NRTI</p><p dir="RTL">تينوفوفير ديسوبروكسيل فيوميرات هو مثبط لأنزيم النســخ&nbsp;العكســـي للنوكليوتيد ، والمعروف عمومًا باسم NRTI</p><p dir="RTL">هذه المواد الفعالة ، والمعروفة أيضًا باسم الأدوية المضادة للفيروسات الرجعية (القهقرية) ، تعمل عن طريق التدخل في عمل إنزيم (إنزيم النسخ العكسي) الذي يعد ضروريًا لتكاثر الفيروس .</p><p dir="RTL"><strong>ترايفيرا أقراص هو علاج لعدوى فيروس نقص المناعة البشري (الإيدز) </strong>في البالغين الذين تتراوح أعمارهم بين 18 سنة وما فوق الذين سبق علاجهم بأدوية أخرى مضادة للفيروسات القهقرية وتمت السيطرة على عدوى فيروس HIV-1 لمدة ثلاثة أشهر على الأقل . يجب ألا يعاني المرضى من فشل العلاج السابق بفيروس نقص المناعة البشرية .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>قبل القيام بتناول أو استعمال </strong><strong>ترايفيرا أقراص :</strong></p><p dir="RTL"><strong>لا تقم باستعمال ترايفيرا أقراص </strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ايفافرنيز ، امتريسيتابين و تينوفوفير ديسوبروكسيل فيوميرات أو أي من المكونات الأخرى لهذا الدواء المدرجة في القسم 6 .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض كبدي حاد .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شكل من تَسَرُّع القَلْب البُطَينِيّ مُتَعَدِّد الأَشْكال ذو خصائص مميزة في&nbsp;تخطيط كهربية القلب مع فَتْراتQ-T &nbsp;مطوّلة الذي يضعك في خطر كبير للإصابة بمشاكل شديدة في ضربات القلب (تورساد دي بوانت) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا توفي أحد أفراد أسرتك (الوالدين أو الأجداد أو الأخوة أو الأخوات) فجأة بسبب مشكلة في القلب أو ولد بمشاكل في القلب .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك طبيبك أن لديك مستويات عالية أو منخفضة من الإلكتروليتات مثل البوتاسيوم أو الماغنيسيوم في الدم .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول حاليا أي من الأدوية التالية (انظر أيضا &quot;أدوية أخرى و ترايفيرا أقراص)</p><p dir="RTL">أستميزول أو تيرفينادين (يستخدم لعلاج حمى الكلأ أو الحساسية الأخرى)</p><p dir="RTL">(البيبريديل (يستخدم لعلاج أمراض القلب</p><p dir="RTL">سيسابريد (يستخدم لعلاج حرقة المعدة)</p><p dir="RTL">قلويدات&nbsp; الإرجوت (على سبيل المثال ، الإرجوتامين ، ديهدروإرجوتامين ، الإرجونوفين ، والميثيل إرجونوفين) (يستخدم لعلاج الصداع النصفي والصداع العنقودي)</p><p dir="RTL">الميدازولام أو تريازولام (يستخدم لمساعدتكم على النوم)</p><p dir="RTL">البيموزيد ، إيميبرامين ، أميتريبتيلين أو كلوميبرامين (يستخدم لعلاج بعض الحالات العقلية)</p><p dir="RTL">نبتة سانت جون (العرن المثقوب) (مستحضر عشبي يستخدم للاكتئاب والقلق)</p><p dir="RTL">(فوريكونازول (يستخدم لعلاج الالتهابات الفطرية</p><p dir="RTL">فليكانيد ، ميتوبرولول (يستخدم لعلاج عدم انتظام ضربات القلب)</p><p dir="RTL">بعض المضادات الحيوية (الماكروليدات ، الفلوروكينولونات ، إميدازول)</p><p dir="RTL">مضادات الفطريات تريازول</p><p dir="RTL">بعض الأدوية المضادة للملاريا</p><p dir="RTL">الميثادون (يستخدم لعلاج إدمان الأفيون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي من هذه الأدوية ، أخبر طبيبك على الفور . تناول هذه الأدوية مع ترايفيرا أقراص يمكن أن يسبب آثار جانبية خطيرة أو تهدد الحياة أو توقف هذه الأدوية عن العمل بشكل كامل .</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong><strong> </strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول ترايفيرا أقراص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يزال بإمكانك نقل فيروس نقص المناعة البشرية عند تناول هذا الدواء ، على الرغم من أن الخطر ينخفض من خلال العلاج الفعال بمضادات الفيروسات القهقرية . ناقش مع طبيبك الاحتياطات اللازمة لتجنب إصابة الآخرين . هذا الدواء ليس علاجا للعدوى بفيروس نقص المناعة البشرية . أثناء تناولك لترايفيرا أقراص ، قد لا تزال تعاني من العدوى أو الأمراض الأخرى المرتبطة بعدوى فيروس نقص المناعة البشرية .</p><p dir="RTL">يجب أن تبقى تحت رعاية طبيبك أثناء تناول ترايفيرا أقراص .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر طبيبك:</p><p dir="RTL">إذا كنت تتناول أدوية أخرى تحتوي على ايفافرنيز أو إمتريسيتابين أو تينوفوفير ديسوبروكسيل أو تينوفوفير ألافيناميد أو لاميفودين أو &nbsp;أديفوفير ديبيفوكسيل . لا ينبغي أن تتناول ترايفيرا أقراص مع أي من هذه الأدوية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض الكلى أو كنت عانيت مسبقا منه ، أو إذا أظهرت الاختبارات وجود مشاكل في كليتيك . لا ينصح بتناول ترايفيرا أقراص إذا كان لديك أمراض الكلى متوسطة إلى شديدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤثر تناول ترايفيرا أقراص بالكلى . قبل بدء العلاج ، قد يطلب الطبيب اختبارات الدم لتقييم وظائف الكلى . قد يطلب الطبيب أيضًا اختبارات الدم أثناء العلاج لمراقبة الكلى .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتناول ترايفيرا أقراص عادةً مع أدوية أخرى يمكن أن تضر بكليتك (انظر تناول الأدوية الأخرى مع ترايفيرا أقراص) . إذا كان هذا لا مفر منه ، فإن طبيبك سيقوم بمراقبة وظائف الكليتين مرة واحدة في الأسبوع .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك اضطراب في القلب ، مثل إشارة كهربائية غير طبيعية تسمى إطالة فترة QT</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من الأمراض العقلية ، بما في ذلك الاكتئاب ، أو من تعاطي المخدرات أو تعاطي الكحول . أخبر طبيبك فورا إذا شعرت بالاكتئاب ، أو لديك أفكار انتحارية أو لديك أفكار غريبة (انظر القسم 4 ، الآثار الجانبية المحتملة) .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من التشنجات (النوبات أو نوبات الصرع) أو إذا كنت تعالج بعلاج مضاد للتشنجات مثل الكاربامازبين والفينوباربيتال والفينيتوين . إذا كنت تتناول أي من هذه الأدوية ، قد يحتاج طبيبك إلى فحص مستوى الدواء المضاد للتشنجات في دمك للتأكد من عدم تأثره أثناء تناول ترايفيرا أقراص . قد يعطيك طبيبك مضاد للتشنجات مختلف .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من مرض الكبد ، بما في ذلك التهاب الكبد المزمن النشط . المرضى الذين يعانون من أمراض الكبد بما في ذلك التهاب الكبد المزمن B أو C ، الذين يعالجون بمضادات الفيروسات القهقرية المختلطة ، يكونون أكثر عرضة لمشكلات الكبد الحادة والمهددة للحياة . قد يقوم طبيبك بإجراء فحوصات الدم من أجل التحقق من وظائف الكبد أو قد يحولك إلى دواء آخر . إذا كنت مصابًا بمرض كبدي حاد ، فلا تتناول ترايفيرا أقراص راجع في القسم 2 سابقًا ، لا تقم باستعمال ترايفيرا أقراص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالتهاب الكبد (ب) ، فإن طبيبك سوف يفكر بعناية في أفضل نظام علاج لك . امتريسيتابين و تينوفوفير ديسوبروكسيل فيوميرات ، وهما من المواد الفعالة في ترايفيرا أقراص ، حيث تظهران بعض النشاط ضد فيروس التهاب الكبد B على الرغم من أن امتريسيتابين غير معتمد لعلاج عدوى التهاب الكبدB &nbsp;قد تصبح أعراض التهاب الكبد الخاص بك أسوأ بعد إيقاف تناول ترايفيرا أقراص . قد يقوم الطبيب بإجراء فحوصات الدم على فترات منتظمة من أجل التحقق من وظائف الكبد (انظر القسم 3 ، التوقفت عن تناول ترايفيرا أقراص)</p><p dir="RTL">استنادا إلى تاريخك المرضي بالكبد ، سيقوم طبيبك بإجراء اختبارات الدم المنتظمة للتحقق من وظائف عمل الكبد .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك يزيد عن 65 عامًا ، فقد تمت دراسة عدد غير كافٍ من المرضى الذين تزيد أعمارهم عن 65 عامًا . إذا كان عمرك يزيد عن 65 عامًا وتم وصف ترايفيرا أقراص لك ، فسيقوم طبيبك بمتابعتك بعناية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بمجرد البدء في تناول ترايفيرا أقراص ، ابحث عن:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات الدوخة ، صعوبة النوم ، النعاس ، صعوبة التركيز أو الحلم غير الطبيعي . قد تبدأ هذه الآثار الجانبية في أول يوم أو يومين من بدء العلاج وتختفي عادة بعد أول أسبوعين إلى أربعة أسابيع .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور أي علامات للطفح الجلدي . قد يكون سبب الطفح ناتج عن تناول ترايفيرا أقراص ، إذا رأيت أي علامات لطفح شديد مع تقرحات أو حمى ، توقف عن تناول ترايفيرا أقراص وأخبر طبيبك فوراً . إذا كنت تعاني من طفح جلدي أثناء تناول NNRTI آخر ، فقد تكون أكثر عرضة للاصابة بالطفح الجلدي أثناء تناول ترايفيرا أقراص .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور أي علامات التهاب أو عدوى . في بعض المرضى الذين يعانون من الإصابة المتقدمة بفيروس نقص المناعة البشرية (الإيدز) وتاريخ العدوى الانتهازية ، قد تظهر علامات وأعراض الالتهابات السابقة بعد وقت قصير من بدء العلاج بمضاد فيروس نقص المناعة البشرية . ويعتقد أن هذه الأعراض ناتجة عن تحسن الاستجابة المناعية في الجسم ، مما يتيح للجسم محاربة الإلتهابات التي قد تكون موجودة بدون أعراض واضحة . إذا لاحظت أي أعراض للعدوى ، يرجى إخبار طبيبك فوراً .</p><p dir="RTL">بالإضافة إلى العدوى الانتهازية ، يمكن أن تحدث اضطرابات المناعة الذاتية (وهي حالة تحدث عندما يهاجم الجهاز المناعي عضوا سليمًا) بعد البدء بتناول الأدوية لعلاج عدوى فيروس نقص المناعة لديك . قد تحدث اضطرابات المناعة الذاتية بعد عدة أشهر من بدء العلاج . إذا لاحظت أي أعراض للعدوى أو أعراض أخرى مثل ضعف العضلات والضعف الذي يبدأ في اليدين والقدمين والانتقال نحو جذع الجسم ، والخفقان ، ورعشة أو فرط النشاط ، يرجى إبلاغ الطبيب على الفور للحصول على العلاج اللازم .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل العظام: بعض المرضى البالغين المصابين بفيروس نقص المناعة البشري والذين يتناولون العلاج بمضاد للفيروسات القهقرية قد يصابون بمرض عظمي يسمى نخر العظم (موت النسيج العظمي الناجم عن فقدان إمدادات الدم إلى العظم) . العلاج لفترة طويلة باستخدام الأدوية المضادة للفيروسات القهقرية ، واستخدام الكورتيكوستيرويد ، واستهلاك الكحول ، وكبت المناعة الشديد ، وزيادة وزن الجسم ، من بين أمور أخرى ، من عوامل الخطر العديدة لتطوير هذا المرض . أعراض التنخر العظمي هي تصلب وأوجاع وآلام المفاصل (خاصةً في الورك والركبة والكتف) وصعوبة الحركة . إذا لاحظت أي من هذه الأعراض أخبر طبيبك .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث مشاكل العظام (التي تتسبب أحيانًا في الكسور) أيضًا بسبب تلف خلايا الكلى&nbsp;الأنبوبية (انظر القسم 4 ، الآثار الجانبية المحتملة) .</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب عدم استخدام ترايفيرا أقراص للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا . لم يتم دراسة ترايفيرا أقراص في الأطفال والمراهقين .</p><p dir="RTL"><strong>تناول أدوية أخرى مع ترايفيرا أقراص </strong></p><p dir="RTL">يجب عدم تناول ترايفيرا أقراص مع بعض الأدوية . يتم سرد هذه الأدوية تحت عنوان لا تقم باستخدام ترايفيرا أقراص ، في بداية القسم 2 . وتشمل بعض الأدوية الشائعة وبعض المستحضرات العشبية (بما في ذلك نبتة سانت جون) التي يمكن أن تسبب تفاعلات خطيرة .</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول ، أو تناولت مؤخرا أو كنت تتناول أي أدوية أخرى .</p><p dir="RTL">أيضا ، ينبغي عدم تناول ترايفيرا أقراص مع أقراص أخرى تحتوي على ايفافرنيز ، امتريسيتابين ، تينوفوفير ديسوبروكسيل ، تينوفوفير&nbsp;أالفينامايد ، أو لاميفودين أو أديفوفير ديبيفوكسيل (إلا إذا أوصى طبيبك) .</p><p dir="RTL"><strong>أخبر طبيبك</strong> إذا كنت تتناول أدوية أخرى قد تضر بكليتك . تشمل بعض الأمثلة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمينوجليكوزيدات ، فانكومايسين (أدوية للعدوى البكتيرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فوسكارنت ، جانسيكلوفير ، سيدوفوفير (أدوية للعدوى الفيروسية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأمفوتريسين B ، البنتاميدين (أدوية للعدوى الفطرية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انترلوكين 2 (لعلاج السرطان)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير المضادة للالتهابات غير الستيرويدية (مضادات الالتهاب غير الستيرويدية ، لتخفيف آلام العظام أو العضلات)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتفاعل ترايفيرا أقراص مع أدوية أخرى ، بما في ذلك المستحضرات العشبية مثل مستخلصات &nbsp;جينكو&nbsp;بيلوبا . امتريسيتابين و تينوفوفير ديسوبروكسيل فيوميرات نتيجة لذلك ، قد تتأثر كميات ايفافرنيز أو الأقراص أو غيرها من الأدوية . هذا قد يمنع أدويتك من العمل بشكل صحيح ، أو قد يجعل أي آثار جانبية أسوأ . في بعض الحالات ، قد يحتاج طبيبك إلى تعديل الجرعة أو فحص مستويات الدم لديك . أخبر طبيبك أو الصيدلي إذا كنت تتناول أيًا مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تحتوي على الديدانوزين (للإصابة بفيروس نقص المناعة البشرية): تناول ترايفيرا أقراص مع أدوية أخرى مضادة للفيروسات والتي تحتوي على دواء ديسانوزين يمكن أن يرفع مستويات دواء الديدانوزين في الدم ويمكن أن يقلل من تعداد الخلايا المناعية CD4 . تم الإبلاغ عن التهاب البنكرياس والحماض اللبني ، والتي تسبب في بعض الأحيان الموت ، نادرا عندما تم تناول الأدوية التي تحتوي على تينوفوفير ديسوبروكسيل و الديدانوزين معا . سوف يفكر طبيبك بعناية في ضرورة تناول تينوفوفير&nbsp; و الديدانوزين .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المستخدمة للإصابة بفيروس نقص المناعة البشرية: مثبطات الإنزيم البروتيني التالية: دارونافير ، إندينافير ، لوبينافير / ريتونافير ، ريتونافير ، أو ريتونافير أتازانافير المعزز&nbsp; أو ساكوئينافير . قد يفكر طبيبك في إعطائك دواءً بديلاً أو تغيير جرعة مثبطات الإنزيم البروتيني . أيضا ، أخبر طبيبك إذا كنت تتناول مارافيروك .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المستخدمة للإصابة بالفيروسات: بوسيبريفير ، سيميبريفير ، سوفوسبوفير / فيلباتاسفير ، سوفوسبوفير / فيلباتاسفير / فوكسيلابريفير .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لخفض مستويات الدهون بالدم (وتسمى أيضا الستاتينات): أتورفاستاتين ، برافاستاتين ، سيمفاستاتين . يمكن أن تقلل ترايفيرا أقراص من كمية الستاتينات في الدم . سيتحقق طبيبك من مستويات الكوليسترول لديك وينظر في تغيير جرعتك من الستاتينات إذا لزم الأمر .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج التشنجات / النوبات (مضادات التشنجات): كاربامازبين ، الفينيتوين ، الفينوباربيتال . يمكن أن يقلل ترايفيرا أقراص كمية مضادات التشنجات في الدم . يمكن أن يقلل الكاربامازبين من كمية ايفافرنيز ، أحد مكونات ترايفيرا أقراص ، في دمك . قد يحتاج طبيبك إلى إعطائك مضاد اختلاج مختلف .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الالتهابات البكتيرية ، بما في ذلك السل و الفطريات المرتبطة بمرض الإيدز: كلاريثرومايسين ، ريفابوتين ، ريفامبيسين . قد يحتاج طبيبك إلى تغيير الجرعة أو إعطائك مضاد حيوي بديل . بالإضافة إلى ذلك ، قد يفكر طبيبك في جرعة إضافية من ايفافرنيز لعلاج عدوى فيروس نقص المناعة لديك .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الالتهابات الفطرية (مضادات الفطريات): إيتراكونازول أو بوساكونازول . يمكن أن تقلل ترايفيرا أقراص من كمية مادة إيتراكونازول أو بوساكونازول في دمك . قد يحتاج طبيبك إلى إعطائك مضادًا مختلفًا للفطريات .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الملاريا: أتوفاكون / وبروجوانيل أو أرتيميثر/لوميفانترين . قد يقلل ترايفيرا أقراص كمية أتوفاكون / وبروجوانيل أو أرتيميثر/لوميفانترين في دمك .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل الهرمونية (على سبيل المثال ، ديبو بروفيرا&nbsp;) ، أو زرع مانع للحمل (على سبيل المثال ، كبسولة الإمبلانون): يجب عليك أيضًا استخدام طريقة موثوق منها واقية لمنع الحمل (انظر الحمل والرضاعة) . قد تتسبب ترايفيرا أقراص في منع موانع الحمل الهرمونية من العمل . وقد حدث الحمل لدى النساء اللواتي يتناولن إفافيرينز ، وهو أحد مكونات ترايفيرا أقراص ، في حين يستخدمن غرسة تحت الجلد لمنع الحمل ، على الرغم من أنه لم يثبت أن العلاج قد تسبب في فشل وسائل منع الحمل .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيرترالين ، وهو دواء يستخدم لعلاج الاكتئاب ، قد يحتاج الطبيب لضبط جرعتك من سيرترالين .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوبروبيون ، وهو دواء يستخدم لعلاج الإكتئاب أو للمساعدة على التوقف عن التدخين قد يحتاج الطبيب لضبط جرعتك من البوبروبيون .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديلتيازيم أو الأدوية المشابهة (حاصرات قنوات الكالسيوم): عند البدء في تناول ترايفيرا أقراص ، قد يحتاج الطبيب لضبط الجرعة من حاصرات قنوات الكالسيوم .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستعملة لمنع رفض زرع الأعضاء (وتسمى أيضا مثبطات المناعة) ، مثل السيكلوسبورين ، سيروليموس وأو تاكروليموس . عندما تبدأ أو تتوقف عن تناول ترايفيرا أقراص سيقوم طبيبك بمراقبة مستويات البلازما الخاصة بك عن كثب .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوارفارين أو أسينوكومارول (الأدوية المستخدمة للحد من تجلط الدم): قد يحتاج الطبيب لضبط الجرعة من الوارفارين أو أسينوكومارول .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلاصة الجينكو بيلوبا (مستحضر عشبي) .</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو في مرحلة الرضاعة الطبيعية ، أو تخطيطين للحمل ، أو تخططين لإنجاب طفل ، اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء .</p><p dir="RTL">يجب على النساء عدم الحمل أثناء العلاج بتناول ترايفيرا أقراص ولمدة 12 أسبوعًا بعد ذلك . قد يطلب منك الطبيب إجراء اختبار الحمل للتأكد من أنك لست حاملاً قبل بدء العلاج باستخدام ترايفيرا أقراص .</p><p dir="RTL">إذا كنت عرضة للحمل أثناء تناول ترايفيرا أقراص ، فأنت بحاجة إلى استخدام وسائل منع الحمل الموثوق بها الواقي (على سبيل المثال ، الواقي الذكري) مع وسائل أخرى لمنع الحمل التي يتم تناولها عن طريق الفم (حبوب منع الحمل) أو غيرها من وسائل منع الحمل الهرمونية (على سبيل المثال ، زرع&nbsp;شريحة&nbsp;منع الحمل ، الحقن) . قد تبقى ايفافرنيز (وهي واحدة من المواد الفعالة لترايفيرا أقراص) في دمك لفترة من الوقت بعد توقف العلاج . لذلك ، يجب عليك الاستمرار في استخدام وسائل منع الحمل ، على النحو الوارد أعلاه ، لمدة 12 أسبوعًا بعد التوقف عن تناول ترايفيرا أقراص .</p><p dir="RTL">أخبر طبيبك فوراً إذا كنت حاملاً أو تنوي الحمل . إذا كنت حاملاً ، يجب أن تتناولي ترايفيرا أقراص فقط إذا قررت أنت وطبيبك أن هناك حاجة واضحة لذلك .</p><p dir="RTL">شوهدت عيوب خلقية خطيرة في الحيوانات التي لم تولد بعد ، وفي أطفال النساء اللواتي عولجوا بتناول إيفافيرنز أثناء الحمل .</p><p dir="RTL">اطلب من طبيبك أو الصيدلي نصيحة قبل تناول أي دواء .</p><p dir="RTL">إذا كنت قد تناولت ترايفيرا أقراص أثناء فترة الحمل ، فقد يطلب الطبيب إجراء فحوصات دم منتظمة واختبارات تشخيصية أخرى لمراقبة نمو طفلك . في الأطفال الذين تناولت أمهاتهم العلاج بمثبطات إنزيم المنتسخة العكسية النوكليوتيدية خلال فترة الحمل ، كانت الفائدة من الحماية ضد فيروس الإيدز أكبر من مخاطر الآثار الجانبية .</p><p dir="RTL">يجب عدم القيام بالرضاعة الطبيعية أثناء العلاج باستخدام ترايفيرا أقراص هذا لأن المادة الفعالة في هذا الدواء تفرز فى حليب الثدي وتسبب أذى خطير لطفلك .</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يتسبب تناول ترايفيرا أقراص في حدوث الدوخة ، وضعف التركيز والنعاس . إذا كنت متأثراً بذلك ، فيجب عليك عدم قيادة السيارة أو تشغيل الآلات .</p><p dir="RTL"><strong>تحتوي ترايفيرا أقراص على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على 1 مل مول (23 .6 ملغم) من الصوديوم لكل قرص والتي يجب أخذها في الاعتبار إذا كنت تستخدم نظامًا غذائيًا مسيطرًا على الصوديوم .</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">تناول ترايفيرا أقراص يمكن أن يسبب الدوخة . إذا شعرت بالدوار أثناء تناول ترايفيرا أقراص ، فلا تقود السيارة ولا تستقل دراجة هوائية ولا تستخدم أي أدوات أو آلات .</p><p dir="RTL"><strong>يحتوي ترايفيرا أقراص على اللاكتوز</strong></p><p dir="RTL"><strong>أخبر طبيبك قبل تناول ترايفيرا أقراص إذا كانت لديك مشاكل من تحمل اللاكتوز أو إذا كان لديك عدم تحمل أي سكريات أخرى .</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك الطبيب أو الصيدلي . تحقق مع طبيبك أو الصيدلي إذا كنت غير متأكد &nbsp;.</p><p dir="RTL"><strong>الجرعة الموصى بها هي:</strong></p><p dir="RTL">قرص واحد يؤخذ كل يوم عن طريق الفم . يجب أن تتناول ترايفيرا أقراص على معدة فارغة . وهذا قد يسبب بعض الآثار الجانبية الأقل إزعاجا (على سبيل المثال ، الدوخة ، والنعاس) .يتم ابتلاع ترايفيرا أقراص كاملة مع الماء .</p><p dir="RTL">يجب تناول ترايفيرا أقراص كل يوم .</p><p dir="RTL">إذا قرر طبيبك إيقاف ترايفيرا أقراص ،</p><p dir="RTL">&nbsp; قد يتم إعطاؤك ايفافرنيز ، امتريسيتابين و/أو تينوفوفير ديسوبروكسيل فيوميرات بشكل منفصل أو مع أدوية أخرى لعلاج عدوى فيروس نقص المناعة لديك .</p><p dir="RTL"><strong>الجرعة الزائدة من ترايفيرا أقراص</strong></p><p dir="RTL">إذا كنت تناولت جرعة زائدة عن طريق الخطأ من ترايفيرا أقراص قد تكون في خطر متزايد من مواجهة الآثار الجانبية لهذا الدواء (انظر القسم 4 ، الآثار الجانبية المحتملة) . اتصل بطبيبك أو أقرب قسم للطوارئ للحصول على المشورة . حافظ على الأقراص معك بحيث يمكنك بسهولة وصف ما قمت به .</p><p dir="RTL"><strong>نسيان تناول أقراص من ترايفيرا أقراص</strong></p><p dir="RTL">من المهم عدم تفويت جرعة من ترايفيرا أقراص إذا نسيت تناول جرعة ما ، حاول معرفة مدة التأخر عن تناول تلك الجرعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت الفترة أقل من 12 ساعة ، تناولها في أقرب وقت ممكن ، ثم تناول الجرعة التالية في وقتها المعتاد .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﻛﺎنت الفترة أﻛﺜﺮ ﻣﻦ ١٢ ﺳﺎﻋﺔ ، فقم بترك الجرعة المنسية و انتظر موعد الجرعة التالية في الوقت العادي لتتناولها . لا تتناول جرعة مضاعفة للتعويض الجرعة المنسية .</p><p dir="RTL">إذا تقيئت خلال أقل من 1 ساعة بعد تناول ترايفيرا أقراص ، فقم بتناول قرص آخر . لا تحتاج إلى تناول قرص آخر إذا حدث التقيؤ بعد فترة أكثر من ساعة بعد تناول ترايفيرا أقراص</p><p dir="RTL"><strong>التوقف عن تناول ترايفيرا أقراص</strong></p><p dir="RTL">لا تتوقف عن تناول ترايفيرا أقراص دون الرجوع إلى طبيبك . إيقاف العلاج باستخدام ترايفيرا أقراص قد يقلل من فعالية العلاج الموصى بها من قبل الطبيب مستقبلا .</p><p dir="RTL">إذا توقفت عن تناول ترايفيرا أقراص ، يجب التحدث مع الطبيب قبل إعادة تناول الأقراص فقد تكون بحاجة إلى تناول ايفافرنيز ، امتريسيتابين و تينوفوفير ديسوبروكسيل فيوميرات بشكل منفصل إذا كنت تواجه مشاكل أو تحتاج إلى تعديل الجرعة .</p><p dir="RTL">ينبغي عدم التوقف عن تناول ترايفيرا أقراص لأي سبب ، هذا مهم جدا لأن كمية الفيروس قد تبدأ في الزيادة إذا توقف الدواء لفترة قصيرة . قد يصبح الفيروس أكثر صعوبة في العلاج .</p><p dir="RTL">إذا كان لديك عدوى فيروس نقص المناعة البشري والتهاب الكبد الوبائي B ، فمن المهم بشكل خاص عدم التوقف عن العلاج بتناول ترايفيرا أقراص دون التحدث إلى طبيبك أولاً . بعض المرضى لديهم اختبارات دم أو أعراض تشير إلى أن التهاب الكبد قد ازداد سوءًا بعد إيقاف امتريسيتابين أو تينوفوفير ديسوبروكسيل وهما اثنان من المكونات الثلاثة لترايفيرا أقراص إذا تم إيقاف تناول ترايفيرا أقراص ، قد يوصي طبيبك باستئناف علاج التهاب الكبد ب . قد تحتاج إلى اختبارات الدم للتأكد من عمل الكبد لمدة 4 أشهر بعد التوقف عن العلاج . في بعض المرضى الذين يعانون من أمراض الكبد المتقدمة أو تليف بالكبد ، لا يوصى بوقف العلاج لأن هذا قد يؤدي إلى تفاقم التهاب الكبد الذي وقد يكون خطراً على حياتك .</p><p dir="RTL">أخبر طبيبك فوراً عن أعراض جديدة أو غير عادية بعد أن تتوقف عن العلاج ، خاصة الأعراض التي تقترن بعدوى التهاب الكبد B ، اتصل بطبيبك قبل إعادة تناول أقراص ترايفيرا أقراص .</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلال علاج فيروس نقص المناعة البشرية ، قد يكون هناك زيادة في الوزن ومستويات الدهون والجلوكوز في الدم . يرتبط هذا جزئيا بالصحة ونمط الحياة ، وتناول أدوية فيروس نقص المناعة البشرية نفسها . سيقوم الطبيب باختبار هذه التغييرات .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها للجميع .</p><p dir="RTL"><strong>الآثار الجانبية المحتملة و الخطيرة: أخبر طبيبك فورا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حماض لاكتيكي معدل حدوثها نادر (يمكن أن يؤثر على شخص من كل 1000 شخص) وهذه أعراض جانبية خطيرة يمكن أن تكون مميتًة . قد تكون الآثار الجانبية التالية أعراض لحدوث ذلك:</p><p dir="RTL">التنفس العميق والسريع</p><p dir="RTL">النعاس</p><p dir="RTL">الشعور بالغثيان والمرض (القيء) وآلام المعدة</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كنت تعتقد أنك مصاب بالحماض لاكتيكي ، فاتصل بطبيبك على الفور .</strong></p><p dir="RTL"><strong>آثار جانبية أخرى خطيرة ومحتملة</strong></p><p dir="RTL">الآثار الجانبية التالية غير شائعة (يمكن أن تؤثر على ما يصل إلى شخص من كل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية (فرط الحساسية) التي قد تسبب تفاعلات جلدية شديدة (متلازمة ستيفنز جونسون ، حمامي عديدة الأشكال ، انظر القسم 2)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والشفتين واللسان أو الحلق</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السلوك الغاضب ، الأفكار الانتحارية ، الأفكار الغريبة ، جنون العظمة ، غير قادر على التفكير بوضوح ، الحالة المزاجية التي تتأثر ، رؤية أو سماع أشياء ليست موجودة بالفعل (الهلوسة) ، محاولات الانتحار ، تغير الشخصية (الذهان) ، كتاتونيا (حالة جمود يكون فيها المريض بلا حركة أوكلام لفترة) .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في البطن (المعدة) ، والناجم عن التهاب البنكرياس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النسيان ، الارتباك ، (النوبات) ، الكلام غير المتناسق ، الرعشة (اهتزاز)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصفرار الجلد أو العين ، والحكة ، أو ألم في البطن (المعدة) الناجم عن التهاب الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف خلايا الكلى الأنبوبية</p><p dir="RTL">الآثار الجانبية النفسية بالإضافة إلى تلك المذكورة أعلاه تشمل الأوهام (المعتقدات الزائفة) ، العصاب . بعض المرضى قاموا بالانتحار . تميل هذه المشاكل إلى الحدوث أكثر في أولئك الذين لديهم تاريخ مرضي عقلي . أخبر طبيبك على الفور إذا كنت تعاني من هذه الأعراض .</p><p dir="RTL">التأثيرات الجانبية للكبد: إذا كنت مصابًا أيضًا بفيروس ، فقد تصاب بتدهور في التهاب الكبد بعد التوقف عن العلاج (انظر القسم 3) .</p><p dir="RTL">الآثار الجانبية التالية نادرة (يمكن أن تؤثر على شخص من كل 1000 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكبدي ، في بعض الحالات يؤدي إلى الموت أو ضرورة زراعة الكبد وذلك في المرضى الذين لديهم أمراض مسبقة بالكبد. ووردت تقارير أيضا عن هذه الآثار الجانبية مع حالات بدون تاريخ مرضي بالكبد .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلى ، بما في ذلك زيادة الحاجه إلى تمرير الكثير من البول والشعور بالعطش</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألام الظهر ، التي قد تحدث بسبب تلف خلايا الكلى الأنبوبية ، بما في ذلك الفشل الكلوي .سوف يقوم طبيبك بعمل اختبارات الدم لمعرفة ما إذا كانت كليتك تعمل بشكل صحيح</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لين العظام ، والتي قد تتسبب في كسور وتحدث نتيجة لتلف خلايا الكلى الأنبوبية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكبد الدهني</p><p dir="RTL"><strong>تحدث إلى طبيبك إذا كنت تعتقد أن لديك أيًا من هذه الآثار الجانبية الخطيرة .</strong></p><p dir="RTL">أكثر الآثار الجانبية حدوثا</p><p dir="RTL">الآثار الجانبية التالية شائعة جدا (يمكن أن تؤثر على أكثر من شخص من كل 10 شخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة ، والصداع ، والإسهال ، والشعور بالغثيان &nbsp;، والإعياء (التقيؤ)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي (بما في ذلك ظهور بقع حمراء مع ظهور تقرحات وتورم في الجلد) ، والتي قد تكون ردود فعل تحسسية .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيضًا قد تظهر نتائج الاختبارات:</p><p dir="RTL">انخفاض في مستويات الفوسفات في الدم</p><p dir="RTL">زيادة مستويات الكرياتين كيناز في الدم التي قد تؤدي إلى آلام في العضلات وضعف</p><p dir="RTL"><strong>آثار جانبية أخرى محتملة</strong></p><p dir="RTL">الآثار الجانبية التالية شائعة (قد تؤثر على مايصل إلى شخص من كل 10 أشخاص) :</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات التوازن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالقلق أو الاكتئاب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صعوبة في النوم ، أحلام غير طبيعية ، صعوبة في التركيز ، النعاس</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المعدة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الهضم مما يؤدي إلى عدم الراحة بعد تناول الوجبات ، والشعور بالانتفاخ والغازات (انتفاخ البطن)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في لون الجلد بما في ذلك سواد الجلد مع ظهور بقع غالبا ما تبدأ على اليدين وباطن القدمين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيضًا قد تظهر الاختبارات:</p><p dir="RTL">انخفاض عدد خلايا الدم البيضاء (يمكن أن يؤدي انخفاض عدد كريات الدم البيضاء إلى جعلك أكثر عرضة للإصابة)</p><p dir="RTL">مشاكل الكبد والبنكرياس</p><p dir="RTL">زيادة الأحماض الدهنية (الدهون الثلاثية) ، البيليروبين أو مستويات السكر في الدم</p><p dir="RTL">الآثار الجانبية التالية غير شائعة (يمكن أن تؤثر على ما يصل إلى شخص من كل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انهيار العضلات أو آلام العضلات أو ضعفها</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (انخفاض عدد خلايا الدم الحمراء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوران أو الإمالة (الدوار) أو صفير أو رنين أو ضوضاء مستمرة في الأذنين .</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبر الثدي عند الذكور</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الدافع الجنسي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشهية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أيضًا قد تظهر الاختبارات:</p><p dir="RTL">انخفاض في البوتاسيوم في الدم</p><p dir="RTL">زيادة في الكرياتينين في الدم</p><p dir="RTL">البروتينات في البول</p><p dir="RTL">زيادة الكولسترول في الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنهيار العضلات ، وتليين العظام (مع آلام العظام وأحيانا يؤدي إلى الكسور) ، ألم العضلات وضعف العضلات وانخفاض في البوتاسيوم أو الفوسفات في الدم والتي تحدث بسبب الضرر بالخلايا الأنبوبية للكلى .</p><p dir="RTL">الآثار الجانبية التالية نادرة (يمكن أن تؤثر على 1 من كل 1000 مريض):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح مثير للحكة في الجلد بسبب رد تحسسي فعل لأشعة الشمس</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة . يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه) . بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء .</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>كيفية تخزين </strong><strong>ترايفيرا أقراص :</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30&deg; مئوية .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بالتخزين في العبوة الأصلية من أجل الحماية من الرطوبة .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم ترايفيرا أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية . يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية . اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة . هذه التدابير تساعد في الحفاظ على البيئة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما تحتويه ترايفيرا أقراص </strong></p><p dir="RTL">المادة الفعالة هي 600 ملغم ايفافرنيز ، 200 ملغم امتريسيتابين و 300 ملغم تينوفوفير ديسوبروكسيل فيوميرات ما يعادل 245 ملغم من تينوفوفير ديسوبروكسيل .</p><p>الصواغات الأخرى هي: اللاكتوز أحادي الهيدرات ، السليلوز دقيق التبلور ، النشا سابق التجلتن ، كروس كارميلوز الصوديوم ، هيدروكسي بروبيل السيلولوز كبريتات الصوديوم اللوريل ، ستيارات الماغنسيوم ، أوبادري II ذو اللون الوردي كود 85F94172 ، المياه النقية .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;<strong>ما هو شكل ترايفيرا أقراص ومحتويات العلبة ؟</strong></p><p dir="RTL">أقراص ذات لون وردي ، على شكل كبسولة ، والأقراص مغلفة بطبقة رقيقة و مدموغة بحرف &#39;H&#39; على جانب واحد و &#39;128&#39; على الجانب الآخر .</p><p dir="RTL"><strong>توافر ترايفيرا أقراص :</strong></p><p dir="RTL">يتوافر ترايفيرا أقراص في عبوات حاوية .</p><p dir="RTL">تحتوي عبوة ترايفيرا أقراص على 30 قرص</p><p dir="RTL">قد لا تتوافر جميع العبوات في السوق المحلي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p>المملكة العربية السعودية .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            9/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Efavirenz, Emtricitabine and Tenofovir disporoxil Fumarate Tablets 600mg/ 200mg/ 300mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Efavirenz, Emtricitabine and Tenofovir disporoxil Fumarate Tablets 600mg/ 200mg/ 300mg:
Each film coated tablet contains 600 mg of Efavirenz USP, 200 mg of Emtricitabine USP and 300 mg of Tenofovir disoproxil fumarate, equivalent to 245 rng of Tenofovir disoproxil. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tenofovir disporoxil Fumarate Tablets 300mg: 
Light Blue coloured, Almond shaped, film coated tablets debossed with 'H' on one side and '123' On other side.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.1</strong><strong> </strong><strong>Therapeutic indications</strong></p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil fumarate. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of &lt; 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets prior to initiation of their first antiretroviral treatment regimen (see sections 4.4 and 5.1).</p><p>The demonstration of the benefit of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (see section 5.1). No data are currently</p><p>&nbsp;</p><p>available from clinical studies with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in treatment-na&iuml;ve or in heavily pretreated patients.</p><p>No data are available to support the combination of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and other antiretroviral agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of HIV infection.</p><p>Posology&nbsp;</p><p>Adults&nbsp;</p><p>The recommended dose of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is one tablet taken orally once daily.</p><p>If a patient misses a dose of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets within 12 hours of the time it is usually taken, the patient should take Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets as soon as possible and resume the normal dosing schedule. If a patient misses a dose of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets by more than 12 hours and it is almost time for the next dose, the patient should not take the missed dose and simply resume the usual dosing schedule.</p><p>If the patient vomits within 1 hour of taking Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets, another tablet should be taken. If the patient vomits more than 1 hour after taking Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets he/she does not need to take another dose.</p><p>It is recommended that Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets be taken on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8). In order to improve the tolerability to efavirenz with respect to undesirable effects on the nervous system, bedtime dosing is recommended (see section 4.8).</p><p>It is anticipated that tenofovir exposure (AUC) will be approximately 30% lower following administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets on an empty stomach as compared to the individual component tenofovir disoproxil when taken with food (see section 5.2). Data on the clinical translation of the decrease in pharmacokinetic exposure are not available. In virologically suppressed patients, the clinical relevance of this reduction can be expected to be limited (see section 5.1).</p><p>Where discontinuation of therapy with one of the components of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is indicated or where dose modification is necessary, separate preparations of efavirenz, emtricitabine and tenofovir disoproxil are available. Please refer to the Summary of Product Characteristics for these medicinal products.</p><p>If therapy with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is discontinued, consideration should be given to the long half-life of efavirenz (see section 5.2) and long intracellular half-lives of emtricitabine and tenofovir. Because of interpatient variability in these parameters and concerns regarding development of resistance, HIV treatment guidelines should be consulted, also taking into consideration the reason for discontinuation.</p><p><em>Dose adjustment:</em> If Efavirenz, Emtricitabine and Tenofovir disporoxil fumarate Tablets is coadministered with rifampicin to patients weighing 50 kg or more, an additional 200 mg/day (800 mg total) of efavirenz may be considered (see section 4.5).</p><p>Special populations&nbsp;</p><p>Elderly&nbsp;</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be administered with caution to elderly patients (see section 4.4).</p><p>Renal impairment&nbsp;</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is not recommended for patients with moderate or severe renal impairment (creatinine clearance (CrCl) &lt; 50 ml/min). Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.4 and 5.2).</p><p>Hepatic impairment&nbsp;</p><p>The pharmacokinetics of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets have not been studied in patients with hepatic impairment. Patients with mild liver disease (Child-Pugh-Turcotte (CPT), Class A) may be treated with the normal recommended dose of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (see sections 4.3, 4.4 and 5.2). Patients should be monitored carefully for adverse reactions, especially nervous system symptoms related to efavirenz (see sections 4.3 and 4.4).</p><p>If Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is discontinued in patients co-infected with HIV and HBV, these patients should be closely monitored for evidence of exacerbation of hepatitis (see section 4.4).</p><p>Paediatric population&nbsp;</p><p>The safety and efficacy of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in children under the age of 18 years have not been established (see section 5.2).</p><p>Method of administration&nbsp;</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be swallowed whole with water, once daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
Severe hepatic impairment (CPT, Class C) (see section 5.2). 
Co-administration with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine). Competition for cytochrome P450 (CYP) 3A4 by efavirenz could result in inhibition of metabolism and create the potential for serious and/or life-threatening adverse reactions (for example, cardiac arrhythmias, prolonged sedation or respiratory depression) (see section 4.5). 
Co-administration with voriconazole. Efavirenz significantly decreases voriconazole plasma concentrations while voriconazole also significantly increases efavirenz plasma concentrations. Since Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is a fixed-dose combination product, the dose of efavirenz cannot be altered (see section 4.5). 
Co-administration with herbal preparations containing St. John's wort (Hypericum perforatum) due to the risk of decreased plasma concentrations and reduced clinical effects of efavirenz (see section 4.5). 
Administration to patients with: 
-	a family history of sudden death or of congenital prolongation of the QTc interval on electrocardiograms, or with any other clinical condition known to prolong the QTc interval. 
-	a history of symptomatic cardiac arrhythmias or with clinically relevant bradycardia or with congestive cardiac failure accompanied by reduced left ventricle ejection fraction. 
-	severe disturbances of electrolyte balance e.g. hypokalemia or hypomagnesemia. 
Co-administration with drugs that are known to prolong the QTc interval (proarrhythmic).  
These drugs include: 
-	antiarrhythmics of classes IA and III, 
-	neuroleptics, antidepressive agents 
-	certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole and triazole antifungal agents, 
-	certain non-sedating antihistamines (terfenadine, astemizole), 
-	cisapride, 
-	flecainide, 
-	certain antimalarials,  
-	methadone (see sections 4.4, 4.5 and 5.1). 
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Co-administration with other medicinal products&nbsp;</p><p>As a fixed combination, Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be administered concomitantly with other medicinal products containing the same active components, emtricitabine or tenofovir disoproxil. Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be co-administered with products containing efavirenz unless needed for dose adjustment e.g. with rifampicin (see section 4.2). Due to similarities with emtricitabine, Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be administered concomitantly with other cytidine analogues, such as lamivudine (see section 4.5). Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be administered concomitantly with adefovir dipivoxil or with medicinal products containing tenofovir alafenamide.</p><p>Co-administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and didanosine is not recommended since exposure to didanosine is significantly increased following co-administration with tenofovir disoproxil that may increase the risk of didanosine-related adverse reactions (see section 4.5). Rarely, pancreatitis and lactic acidosis, sometimes fatal have been reported.</p><p>Co-administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended since plasma concentrations of velpatasvir and voxilaprevir are expected to decrease following coadministration with efavirenz leading to reduced therapeutic effect of sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir (see section 4.5).</p><p>No data are available on the safety and efficacy of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in combination with other antiretroviral agents.</p><p>Concomitant use of Ginkgo biloba extracts is not recommended (see section 4.5).</p><p>Switching from a PI-based antiretroviral regimen&nbsp;</p><p>Currently available data indicate a trend that in patients on a PI-based antiretroviral regimen the switch to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets may lead to a reduction of the response to the therapy (see section 5.1). These patients should be carefully monitored for rises in viral load and, since the safety profile of efavirenz differs from that of protease inhibitors, for adverse reactions</p><p>Opportunistic infections&nbsp;</p><p>Patients receiving Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.</p><p>Transmission of HIV&nbsp;</p><p>While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance with national guidelines.</p><p>Effect of food&nbsp;</p><p>The administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in frequency of adverse reactions (see section 4.8). It is recommended that Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets be taken on an empty stomach, preferably at bedtime.</p><p>Liver disease&nbsp;</p><p>The pharmacokinetics, safety and efficacy of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets have not been established in patients with significant underlying liver disorders (see section 5.2). Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is contraindicated in patients with severe hepatic impairment (see section 4.3) and not recommended in patients with moderate hepatic impairment. Since efavirenz is principally metabolised by the CYP system, caution should be exercised in administering Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets to patients with mild hepatic impairment. These patients should be carefully monitored for efavirenz adverse reactions, especially nervous system symptoms. Laboratory tests should be performed to evaluate their liver disease at periodic intervals (see section 4.2).</p><p>Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. If there is evidence of worsening liver disease or persistent elevations of serum transaminases to greater than 5 times the upper limit of the normal range, the benefit of continued therapy with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets needs to be weighed against the potential risks of significant liver toxicity. In such patients, interruption or discontinuation of treatment must be considered (see section 4.8).&nbsp;</p><p>In patients treated with other medicinal products associated with liver toxicity, monitoring of liver enzymes is also recommended.</p><p>Hepatic events&nbsp;</p><p>Post-marketing reports of hepatic failure also occurred in patients with no pre-existing hepatic disease or other identifiable risk factors (see section 4.8). Liver enzyme monitoring should be considered for all patients independent of pre-existing hepatic dysfunction or other risk factors.</p><p>Patients with HIV and hepatitis B (HBV) or C virus (HCV) co-infection&nbsp;</p><p>Patients with chronic hepatitis B or C and treated with CART are at an increased risk for severe and potentially fatal hepatic adverse reactions.&nbsp;</p><p>Physicians should refer to current HIV treatment guidelines for the optimal management of HIV infection in patients co-infected with HBV.</p><p>In case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant Summary of Product Characteristics for these medicinal products.</p><p>The safety and efficacy of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets have not been studied for the treatment of chronic HBV infection. Emtricitabine and tenofovir individually and in combination have shown activity against HBV in pharmacodynamic studies (see section 5.1). Limited clinical experience suggests that emtricitabine and tenofovir disoproxil have an anti-HBV activity when used in antiretroviral combination therapy to control HIV infection. Discontinuation of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis. Patients co-infected with HIV and HBV who discontinue Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets must be closely monitored with both clinical and laboratory follow-up for at least four months after stopping treatment with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. If appropriate, resumption of antihepatitis B therapy may be warranted. In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.</p><p>QTc Prolongation&nbsp;</p><p>QTc prolongation has been observed with the use of efavirenz (see sections 4.5 and 5.1). For patients at increased risk of Torsade de Pointes or who are receiving drugs with a known risk for Torsade de Pointes, consider alternatives to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets.</p><p>Psychiatric symptoms&nbsp;</p><p>Psychiatric adverse reactions have been reported in patients treated with efavirenz. Patients with a prior history of psychiatric disorders appear to be at greater risk of serious psychiatric adverse reactions. In particular, severe depression was more common in those with a history of depression. There have also been post-marketing reports of severe depression, death by suicide, delusions, psychosis-like behaviour, and catatonia. Patients should be advised that if they experience symptoms such as severe depression, psychosis or suicidal ideation, they should contact their doctor immediately to assess the possibility that the symptoms may be related to the use of efavirenz, and if so, to determine whether the risk of continued therapy outweighs the benefits (see section 4.8).</p><p>Nervous system symptoms&nbsp;</p><p>Symptoms including, but not limited to, dizziness, insomnia, somnolence, impaired concentration and abnormal dreaming are frequently reported undesirable effects in patients receiving efavirenz 600 mg daily in clinical studies. Dizziness was also seen in clinical studies with emtricitabine and tenofovir disoproxil. Headache has been reported in clinical studies with emtricitabine (see section 4.8). Nervous system symptoms associated with efavirenz usually begin during the first one or two days of therapy and generally resolve after the first two to four weeks. Patients should be informed that if they do occur, these common symptoms are likely to improve with continued therapy and are not predictive of subsequent onset of any of the less frequent psychiatric symptoms.</p><p>Seizures&nbsp;</p><p>Convulsions have been observed in patients receiving efavirenz, generally in the presence of a known medical history of seizures. Patients who are receiving concomitant anticonvulsant medicinal products primarily metabolised by the liver, such as phenytoin, carbamazepine and phenobarbital, may require periodic monitoring of plasma levels. In a drug interaction study, carbamazepine plasma concentrations were decreased when carbamazepine was co-administered with efavirenz (see section 4.5). Caution must be taken in any patient with a history of seizures <u>Renal impairment</u>&nbsp;</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is not recommended for patients with moderate or severe renal impairment (creatinine clearance &lt; 50 ml/min). Patients with moderate or severe renal impairment require a dose adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and</p><p>5.2). Use of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be avoided with concurrent or recent use of a nephrotoxic medicinal product. If concomitant use of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and nephrotoxic agents (e.g. aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir, interleukin-2) is unavoidable, renal function must be monitored weekly (see section 4.5).</p><p>Cases of acute renal failure after initiation of high dose or multiple non-steroidal antiinflammatory drugs (NSAIDs) have been reported in patients treated with tenofovir disoproxil and with risk factors for renal dysfunction. If Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is co-administered with an NSAID, renal function should be monitored adequately.</p><p>Renal failure, renal impairment, elevated creatinine, hypophosphatemia and proximal tubulopathy (including Fanconi syndrome) have been reported with the use of tenofovir disoproxil in clinical practice (see section 4.8).</p><p>It is recommended that creatinine clearance is calculated in all patients prior to initiating therapy with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and renal function (creatinine clearance and serum phosphate) is also monitored after two to four weeks of treatment, after three months of treatment and every three to six months thereafter in patients without renal risk factors. In patients with a history of renal dysfunction or in patients who are at risk of renal dysfunction, a more frequent monitoring of renal function is required</p><p>If serum phosphate is &lt; 1.5 mg/dl (0.48 mmol/l) or creatinine clearance is decreased to &lt; 50 ml/min in any patient receiving Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets, renal function must be re-evaluated within one week, including measurements of blood glucose, blood potassium and urine glucose concentrations (see section 4.8, proximal tubulopathy). Since Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is a combination product and the dosing interval of the individual components cannot be altered, treatment with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets must be interrupted in patients with confirmed creatinine clearance &lt; 50 ml/min or decreases in serum phosphate to &lt; 1.0 mg/dl (0.32 mmol/l). Interrupting treatment with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should also be considered in case of progressive decline of renal function when no other cause has been identified. Where discontinuation of therapy with one of the components of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is indicated or where dose modification is necessary, separate preparations of efavirenz, emtricitabine and tenofovir disoproxil are available</p><p>Bone effects&nbsp;</p><p>In a 144-week controlled clinical study that compared tenofovir disoproxil with stavudine in combination with lamivudine and efavirenz in antiretroviral-na&iuml;ve patients, small decreases in bone mineral density of the hip and spine were observed in both treatment groups. Decreases in bone mineral density of spine and changes in bone biomarkers from baseline were significantly greater in the tenofovir disoproxil treatment group at 144 weeks. Decreases in bone mineral density of the hip were significantly greater in this group until 96 weeks. However, there was no increased risk of fractures or evidence for clinically relevant bone abnormalities over 144 weeks.</p><p>In other studies (prospective and cross-sectional), the most pronounced decreases in BMD were seen in patients treated with tenofovir disoproxil as part of a regimen containing a boosted protease inhibitor. Alternative treatment regimens should be considered for patients with osteoporosis that are at a high risk for fractures.</p><p>Bone abnormalities (infrequently contributing to fractures) may be associated with proximal renal tubulopathy (see section 4.8). If bone abnormalities are suspected then appropriate consultation should be obtained</p><p>Skin reactions&nbsp;</p><p>Mild-to-moderate rash has been reported with the individual components of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. The rash associated with the efavirenz component usually resolves with continued therapy. Appropriate antihistamines and/or corticosteroids may improve tolerability and hasten the resolution of rash. Severe rash associated with blistering, moist desquamation or ulceration has been reported in less than 1% of patients treated with efavirenz (see section 4.8). The incidence of erythema multiforme or StevensJohnson syndrome was approximately 0.1%. Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets must be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement or fever. Experience with efavirenz in patients who discontinued other antiretroviral agents of the NNRTI class is limited. Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is not recommended for patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson syndrome) while taking an NNRTI.</p><p>Weight and metabolic parameters&nbsp;</p><p>An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and life style. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate</p><p>Mitochondrial dysfunction following exposure <em>in utero</em><em> </em>&nbsp;</p><p>Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV negative infants exposed <em>in utero</em> and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia). These events have often been transitory. Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed <em>in utero</em> to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV</p><p>Immune Reactivation Syndrome&nbsp;</p><p>In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalized and/or focal mycobacterial infections, and <em>Pneumocystis</em> <em>jirovecii</em> pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.</p><p>Autoimmune disorders (such as Graves&#39; disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment</p><p>Osteonecrosis&nbsp;</p><p>Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p>Patients with HIV-1 harbouring mutations&nbsp;</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be avoided in patients with HIV-1 harbouring the K65R, M184V/I or K103N mutation (see sections 4.1 and</p><p>5.1).</p><p>Elderly&nbsp;</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets has not been studied in patients over the age of 65. Elderly patients are more likely to have decreased hepatic or renal function, therefore caution should be exercised when treating elderly patients with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (see section 4.2).</p><p>Excipients&nbsp;</p><p>This medicinal product contains 1 mmol (23.6 mg) of sodium per dose which should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets contains efavirenz, emtricitabine and tenofovir disoproxil, any interactions that have been identified with these agents individually may occur with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. Interaction studies with these agents have only been performed in adults.</p><p>As a fixed combination, Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be administered concomitantly with other medicinal products containing the components, emtricitabine or tenofovir disoproxil. Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be co-administered with products containing efavirenz unless needed for dose adjustment e.g. with rifampicin (see section 4.2). Due to similarities with emtricitabine, Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be administered concomitantly with other cytidine analogues, such as lamivudine. Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be administered concomitantly with adefovir dipivoxil or with medicinal products containing tenofovir alafenamide.</p><p>Efavirenz is an<em> in vivo</em> inducer of CYP3A4, CYP2B6 and UGT1A1. Compounds that are substrates of these enzymes may have decreased plasma concentrations when co-administered with efavirenz. Efavirenz may be an inducer of CYP2C19 and CYP2C9; however, inhibition has also been observed <em>in vitro</em> and the net effect of co-administration with substrates of these enzymes is not clear (see section 5.2).</p><p>Efavirenz exposure may be increased when given with medicinal products (for example ritonavir) or food (for example, grapefruit juice) which inhibit CYP3A4 or CYP2B6 activity. Compounds or herbal preparations (for example Ginkgo biloba extracts and St. John&#39;s wort) which induce these enzymes may give rise to decreased plasma concentrations of efavirenz.</p><p>Concomitant use of St. John&#39;s wort is contraindicated (see section 4.3). Concomitant use of Ginkgo biloba extracts is not recommended (see section 4.4).</p><p><em>In vitro</em> and clinical pharmacokinetic interaction studies have shown the potential for CYPmediated interactions involving emtricitabine and tenofovir disoproxil with other medicinal products is low</p><p>Cannabinoid test interaction&nbsp;</p><p>Efavirenz does not bind to cannabinoid receptors. False-positive urine cannabinoid test results have been reported with some screening assays in uninfected and HIV infected subjects receiving efavirenz. Confirmatory testing by a more specific method such as gas chromatography/mass spectrometry is recommended in such cases.</p><p>Contraindications of concomitant use&nbsp;</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets must not be administered concurrently with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine), since inhibition of their metabolism may lead to serious, life-threatening events (see section 4.3).</p><p><em>Voriconazole:</em> Co-administration of standard doses of efavirenz and voriconazole is</p><p>contraindicated. Since Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is a fixed-dose combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets must not be coadministered (see section 4.3 and Table 1).</p><p><em>St. John&#39;s wort (Hypericum perforatum):</em> Co-administration of Efaverinz, emitracitabine and</p><p>Tenofovir disporoxil fumarate Tablets and St. John&#39;s wort or herbal preparations containing St. John&#39;s wort is contraindicated. Plasma levels of efavirenz can be reduced by concomitant use of St. John&#39;s wort due to induction of drug metabolising enzymes and/or transport proteins by St. John&#39;s wort. If a patient is already taking St. John&#39;s wort, stop St. John&#39;s wort, check viral levels and if possible efavirenz levels. Efavirenz levels may increase on stopping St. John&#39;s wort. The inducing effect of St. John&#39;s wort may persist for at least 2 weeks after cessation of treatment (see section 4.3).</p><p><em>QT Prolonging Drugs: </em>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes, such as: antiarrhythmics of classes IA and III, neuroleptics and antidepressant agents, certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain non-sedating antihistaminics (terfenadine, astemizole), cisapride, flecainide, certain antimalarials and methadone (see section 4.3).</p><p>Concomitant use not recommended&nbsp;</p><p><em>Atazanavir/ritonavir:</em> Insufficient data are available to make a dosing recommendation for atazanavir/ritonavir in combination with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. Therefore co-administration of atazanavir/ritonavir and Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is not recommended (see Table 1).</p><p><em>Didanosine:</em> Co-administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and didanosine is not recommended (see section 4.4 and Table 1).</p><p><em>Sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir</em>: Co-administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended (see section 4.4 and Table 1)</p><p><em>Renally eliminated medicinal products:</em> Since emtricitabine and tenofovir are primarily eliminated by the kidneys, co-administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets with medicinal products that reduce renal function or compete for active tubular secretion (e.g. cidofovir) may increase serum concentrations of emtricitabine, tenofovir and/or the co-administered medicinal products</p><p>Use of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be avoided with concurrent or recent use of a nephrotoxic medicinal product. Some examples include, but are not limited to, aminoglycosides, amphotericin B, foscarnet, ganciclovir, pentamidine, vancomycin, cidofovir or interleukin-2 (see section 4.4).</p><p>Other interactions&nbsp;</p><p>Interactions between Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets or its individual component(s) and other medicinal products are listed in Table 1 below (increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;, no change as &ldquo;&harr;&rdquo;, twice daily as &ldquo;b.i.d.&rdquo;, once daily as &ldquo;q.d.&rdquo; and once every 8 hours as &ldquo;q8h&rdquo;). If available, 90% confidence intervals are shown in parentheses.</p><p>Table 1: Interactions between Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets or its individual components and other medicinal products</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product by therapeutic </strong></p><p><strong>areas </strong></p></td><td style="vertical-align:top"><p><strong>Effects on drug levels </strong></p><p><strong>Mean percent change in AUC, </strong></p><p><strong>C<sub>max</sub>, C<sub>min</sub> with 90% confidence intervals if available </strong></p><p><strong>(mechanism) </strong></p></td><td style="vertical-align:top"><p><strong>Recommendation concerning co-</strong></p><p><strong>administration with </strong></p><p><strong>Efaverinz, emitracitabine and </strong></p><p><strong>Tenofovir disporoxil fumarate Tablets </strong></p><p><strong>(efavirenz 600 mg, emtricitabine 200 mg, </strong></p><p><strong>tenofovir disoproxil 245 </strong></p><p><strong>mg) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ANTI-INFECTIVES</em>&nbsp; </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HIV antivirals&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Protease inhibitors&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Atazanavir/ritonavir/Tenofovir disoproxil</p><p>(300 mg q.d./100 mg q.d./245 mg q.d.)</p></td><td style="vertical-align:top"><p>Atazanavir:</p><p>AUC: &darr; 25% (&darr; 42 to &darr; 3)</p><p>C<sub>max</sub>: &darr; 28% (&darr; 50 to &uarr; 5)</p><p>C<sub>min</sub>: &darr; 26% (&darr; 46 to &uarr; 10)</p><p>Co-administration of atazanavir/ritonavir with tenofovir resulted in increased exposure to tenofovir. Higher tenofovir concentrations could potentiate tenofovir-associated adverse events, including renal disorders.</p></td><td rowspan="2" style="vertical-align:top"><p>Co-administration &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>atazanavir/ritonavir and Efaverinz, emitracitabine and Tenofovir disporoxil&nbsp; fumarate Tablets is not&nbsp; recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/ritonavir/Efavirenz</p><p>(400 mg q.d./100 mg q.d./600 mg q.d., all administered with food)</p><p>Atazanavir/ritonavir/Efavirenz</p><p>(400 mg q.d./200 mg q.d./600 mg q.d., all administered with food)</p></td><td style="vertical-align:top"><p>Atazanavir (pm):</p><p>AUC: &harr;* (&darr; 9% to &uarr; 10%) C<sub>max</sub>: &uarr; 17%* (&uarr; 8 to &uarr; 27) C<sub>min</sub>: &darr; 42%* (&darr; 31 to &darr; 51) Atazanavir (pm):</p><p>AUC: &harr;*/** (&darr; 10% to &uarr; 26%)</p><p>C<sub>max</sub>: &harr;*/** (&darr; 5% to &uarr; 26%) C<sub>min</sub>: &uarr; 12%*/** (&darr; 16 to &uarr; 49) (CYP3A4 induction).</p><p>* When compared to atazanavir 300 mg/ritonavir 100 mg q.d. in the evening without efavirenz. This decrease in atazanavir C<sub>min</sub> might negatively impact the efficacy of atazanavir.</p><p>** based on historical comparison.</p><p>Co-administration of efavirenz with</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>atazanavir/ritonavir recommended.</p></td><td style="vertical-align:top"><p>is</p></td><td style="vertical-align:top"><p>not</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/ritonavir/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/ritonavir/Efavirenz</p><p>(300 mg b.i.d.*/100 mg b.i.d./600 mg q.d.)</p><p>*lower than recommended doses; similar findings are expected with recommended doses.</p></td><td style="vertical-align:top"><p>Darunavir:</p><p>&nbsp;AUC: &darr; 13%</p><p>C<sub>min</sub>: &darr; 31%</p><p>&nbsp;C<sub>max</sub>: &darr; 15%</p><p>&nbsp;(CYP3A4 induction) Efavirenz:</p><p>AUC: &uarr; 21%</p><p>C<sub>min</sub>: &uarr; 17%</p><p>C<sub>max</sub>: &uarr; 15%</p><p>(CYP3A4 inhibition)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in combination with</p><p>darunavir/ritonavir</p><p>800/100 mg once daily may result in suboptimal</p><p>darunavir &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; C<sub>min</sub>. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is to be used in combination with darunavir/ritonavir, the darunavir/ritonavir</p><p>600/100 mg twice daily regimen should be used. Darunavir/ritonavir</p><p>should &nbsp;&nbsp;&nbsp; be &nbsp;&nbsp; used &nbsp;&nbsp;&nbsp; with</p><p>&nbsp;</p><p>caution in combination with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. See ritonavir row below. Monitoring of renal</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/ritonavir/Tenofovir disoproxil</p><p>(300 mg b.i.d.*/100 mg b.i.d./245 mg q.d.)</p><p>*lower than recommended dose</p></td><td style="vertical-align:top"><p>Darunavir:</p><p>&nbsp;AUC: &harr;</p><p>Cmin: &harr;</p><p>Tenofovir:</p><p>AUC: &uarr; 22%</p><p>C<sub>min</sub>: &uarr; 37%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/ritonavir/Emtricitabine</p></td><td colspan="3" style="vertical-align:top"><p>Interaction not studied. Based on the different elimination pathways, no interaction is expected.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>function may be indicated, particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir/ritonavir/Efavirenz (700 mg b.i.d./100 mg b.i.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>No clinically significant&nbsp; pharmacokinetic interaction.</p></td><td rowspan="3" style="vertical-align:top"><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and</p><p>fosamprenavir/ritonavir can be co-administered without dose adjustment.</p><p>See ritonavir row below.</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir/ritonavir/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir/ritonavir/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir/Efavirenz</p><p>(800 mg q8h/200 mg q.d.)</p></td><td style="vertical-align:top"><p>Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Indinavir:</p><p>AUC: &darr; 31% (&darr; 8 to &darr; 47)</p><p>C<sub>min</sub>: &darr; 40%</p><p>A similar reduction in indinavir exposures &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; was &nbsp;&nbsp;&nbsp;&nbsp; observed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when indinavir 1,000 mg q8h was given with efavirenz 600 mg q.d.</p><p>(CYP3A4 induction)</p><p>For co-administration of efavirenz with low-dose ritonavir in combination with a protease inhibitor,</p></td><td style="vertical-align:top"><p>Insufficient data are available to make a dosing recommendation for indinavir when dosed with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. While the clinical significance&nbsp; of decreased indinavir concentrations has not been established, the&nbsp; magnitude of the&nbsp; observed pharmacokinetic&nbsp; interaction should be</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>see section on ritonavir below.</p></td><td rowspan="3" style="vertical-align:top"><p>taken into consideration when choosing a regimen containing both efavirenz,</p><p>a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; component &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets, and indinavir.</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir/Emtricitabine</p><p>(800 mg q8h/200 mg q.d.)</p></td><td style="vertical-align:top"><p>Indinavir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir/Tenofovir disoproxil</p><p>(800 mg q8h/245 mg q.d.)</p></td><td style="vertical-align:top"><p>Indinavir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Tenofovir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir/ritonavir/Tenofovir disoproxil (400 mg b.i.d./100 mg b.i.d./245 mg q.d.)</p></td><td style="vertical-align:top"><p>Lopinavir/Ritonavir:</p><p>&nbsp;AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Tenofovir:</p><p>AUC: &uarr; 32% (&uarr; 25 to &uarr; 38)</p><p>Cmax: &harr;</p><p>C<sub>min</sub>: &uarr; 51% (&uarr; 37 to &uarr; 66)</p><p>Higher tenofovir concentrations could potentiate &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tenofovir-associated adverse &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; events, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; renal disorders.</p></td><td style="vertical-align:top"><p>Insufficient data are available to make a dosing recommendation for lopinavir/ritonavir when dosed with</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. Co-</p><p>&nbsp;administration of&nbsp; lopinavir/ritonavir and&nbsp; Efaverinz, emitracitabine and Tenofovir disporoxil</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Lopinavir/ritonavir soft capsules or oral solution/Efavirenz</p><p>&nbsp;</p><p>Lopinavir/ritonavir tablets/Efavirenz</p><p>(400/100 mg b.i.d./600 mg q.d.)</p><p>(500/125 mg b.i.d./600 mg q.d.)</p></td><td colspan="2" style="vertical-align:bottom"><p>Substantial decrease in lopinavir exposure, necessitating dosage adjustment of lopinavir/ritonavir. When used in combination with efavirenz and two NRTIs, 533/133 mg lopinavir/ritonavir (soft capsules) twice daily yielded similar lopinavir plasma concentrations as compared to lopinavir/ritonavir (soft capsules) 400/100 mg twice daily without efavirenz (historical data).</p><p>Lopinavir concentrations: &darr; 30-40% Lopinavir concentrations: similar to lopinavir/ritonavir 400/100 mg twice daily without efavirenz. Dosage adjustment of lopinavir/ritonavir is necessary when given with efavirenz. For co-administration of efavirenz with low-dose ritonavir in combination with a protease inhibitor, see section on ritonavir below.</p></td><td style="vertical-align:top"><p>fumarate Tablets is not recommended.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Lopinavir/ritonavir/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ritonavir/Efavirenz</p><p>(500 mg b.i.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Ritonavir:</p><p>Morning AUC: &uarr; 18% (&uarr; 6 to &uarr; 33)</p><p>Evening AUC: &harr;</p><p>Morning Cmax: &uarr; 24% (&uarr; 12 to &uarr; 38)</p><p>Evening Cmax: &harr;</p><p>Morning Cmin: &uarr; 42% (&uarr; 9 to &uarr; 86)</p><p>Evening Cmin: &uarr; 24% (&uarr; 3 to &uarr; 50) Efavirenz:</p></td><td style="vertical-align:top"><p>Co-administration ritonavir at doses of 600 mg and Efaverinz,</p><p>emitracitabine</p><p>Tenofovir disporoxil fumarate Tablets is not recommended. When using Efaverinz,</p></td><td style="vertical-align:top"><p>of</p><p>and</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AUC: &uarr; 21% (&uarr; 10 to &uarr; 34)</p><p>Cmax: &uarr; 14% (&uarr; 4 to &uarr; 26)</p><p>Cmin: &uarr; 25% (&uarr; 7 to &uarr; 46)</p><p>(inhibition &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CYP-mediated</p><p>oxidative metabolism)</p><p>When efavirenz was given with ritonavir 500 mg or 600 mg twice daily, the combination was not well tolerated (for example, dizziness, nausea, paraesthesia and elevated liver enzymes occurred). Sufficient data on the tolerability of efavirenz with low-dose ritonavir (100 mg, once or twice daily) are not available.</p></td><td rowspan="3" style="vertical-align:top"><p>emitracitabine</p><p>Tenofovir disporoxil fumarate Tablets <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_83338"
   o:spid="_x0000_s1030" style='width:24.35pt;height:10.9pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="309190,138633" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:rect id="Rectangle_x0020_9277" o:spid="_x0000_s1031" style='position:absolute;
    width:411222;height:184382;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
       margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
       line-height:107%'>with <o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><w:wrap type="none" anchorx="page"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="46" height="22" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1027" type="#_x0000_t75" style='width:24.35pt;height:10.9pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]-->low-dose ritonavir, the possibility of an increase</p><p>&nbsp;in the incidence&nbsp; efavirenz-associated&nbsp; adverse events should be&nbsp; considered, due&nbsp; possible&nbsp; pharmacodynamic&nbsp; interaction.</p><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>and of</p><p>to</p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Ritonavir/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Saquinavir/ritonavir/Efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied. For coadministration of efavirenz with lowdose ritonavir in combination with a protease inhibitor, see section on ritonavir above.</p></td><td colspan="2" rowspan="3" style="vertical-align:top"><p>Insufficient data are available to make a&nbsp; dosing recommendation for saquinavir/ritonavir when dosed with</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. Coadministration of</p><p>saquinavir/ritonavir and Efaverinz, emitracitabine</p></td></tr><tr><td style="vertical-align:top"><p>Saquinavir/ritonavir/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-</p><p>administered with ritonavir boosted saquinavir.</p></td></tr><tr><td style="vertical-align:top"><p>Saquinavir/ritonavir/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>and Tenofovir disporoxil fumarate Tablets is not recommended. Use of</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in combination with saquinavir as the sole protease inhibitor is not recommended.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>CCR5 antagonist&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Maraviroc/Efavirenz</p><p>(100 mg b.i.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Maraviroc:</p><p>AUC12h: &darr; 45% (&darr; 38 to &darr; 51)</p><p>Cmax: &darr; 51% (&darr; 37 to &darr; 62)</p><p>Efavirenz &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concentrations</p><p>measured, no effect is expected.</p></td><td style="vertical-align:bottom"><p>not</p></td><td rowspan="3" style="vertical-align:top"><p>Refer to the Summary of Product Characteristics for the medicinal product containing maraviroc.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Maraviroc/Tenofovir disoproxil</p><p>(300 mg b.i.d./245 mg q.d.)</p></td><td style="vertical-align:top"><p>Maraviroc:</p><p>AUC12h: &harr;</p><p>Cmax: &harr;</p><p>Tenofovir &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; concentrations</p><p>measured, no effect is expected.</p></td><td style="vertical-align:bottom"><p>not</p></td></tr><tr><td style="vertical-align:top"><p>Maraviroc/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Integrase strand transfer inhibitor&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Raltegravir/Efavirenz</p><p>(400 mg single dose/-)</p></td><td style="vertical-align:top"><p>Raltegravir:</p><p>AUC: &darr; 36%</p><p>C12h: &darr; 21%</p><p>Cmax: &darr; 36%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and raltegravir can be co-</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(UGT1A1 induction)</p></td><td rowspan="3" style="vertical-align:top"><p>administered &nbsp; without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Raltegravir/Tenofovir disoproxil</p><p>(400 mg b.i.d./-)</p></td><td style="vertical-align:top"><p>Raltegravir:</p><p>AUC: &uarr; 49%</p><p>C12h: &uarr; 3%</p><p>Cmax: &uarr; 64%</p><p>(mechanism of interaction unknown) Tenofovir:</p><p>AUC: &darr; 10%</p><p>C12h: &darr; 13%</p><p>Cmax: &darr; 23%</p></td></tr><tr><td style="vertical-align:top"><p>Raltegravir/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>NRTIs and NNRTIs&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>NRTIs/Efavirenz</p></td><td style="vertical-align:top"><p>Specific interaction studies have not been performed with efavirenz and NRTIs other than lamivudine, zidovudine and tenofovir disoproxil. Clinically significant interactions have not been found and would not be expected since the NRTIs are metabolised via a different route than efavirenz and would be unlikely to compete for the same metabolic enzymes and elimination pathways.</p></td><td style="vertical-align:top"><p>&nbsp;Due to the similarity&nbsp; between lamivudine and&nbsp; emtricitabine, a&nbsp; component of Efaverinz,&nbsp; emitracitabine and&nbsp; Tenofovir disporoxil &nbsp;fumarate Tablets,</p><p>&nbsp;Efaverinz, emitracitabine&nbsp; and Tenofovir disporoxil&nbsp; fumarate Tablets should not be administered concomitantly with lamivudine (see section</p><p>4.4).</p></td></tr><tr><td style="vertical-align:top"><p>NNRTIs/Efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>Since use of two NNRTIs</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>proved not beneficial in terms of efficacy and safety, co-administration of Efaverinz,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>emitracitabine</p><p>Tenofovir &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disporoxil</p></td><td style="vertical-align:top"><p>and</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fumarate Tablets another NNRTI is not recommended.</p></td><td style="vertical-align:top"><p>and</p></td></tr><tr><td style="vertical-align:top"><p>Didanosine/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Co-administration of tenofovir disoproxil and didanosine results in a</p><p>40-60% increase in systemic exposure to didanosine that may increase the risk for didanosinerelated adverse reactions. Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported. Co-administration of tenofovir disoproxil and didanosine at a dose of 400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) didanosine. A decreased dosage of 250 mg didanosine co-administered with tenofovir disoproxil therapy has been associated with reports of high</p></td><td colspan="2" style="vertical-align:top"><p>Co-administration &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>&nbsp;Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and didanosine is not recommended (see&nbsp; section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>rates of virologic failure within several tested combinations.</p></td><td colspan="2" rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Didanosine/Efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Didanosine/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hepatitis C antivirals&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Boceprevir/Efavirenz</p><p>(800 mg q8h/600 mg q.d.)</p></td><td style="vertical-align:top"><p>Boceprevir:</p><p>AUC: &harr; 19%*</p><p>Cmax: &harr; 8%</p><p>Cmin: &darr; 44% Efavirenz:</p><p>AUC: &harr; 20%</p><p>Cmax: &harr; 11%</p><p>(CYP3A &nbsp;&nbsp;&nbsp; induction &nbsp;&nbsp; -</p><p>boceprevir)&nbsp;</p><p>*0-8 hours</p><p>No effect (&harr;) equals a decrease in mean ratio estimate of &le; 20% or increase in mean ratio estimate of &le; 25%.</p></td><td><p>effect</p></td><td><p>on</p></td><td style="vertical-align:top"><p>Plasma &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trough</p><p>concentrations</p><p>boceprevir were decreased when</p><p>administered &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_82491"
   o:spid="_x0000_s1028" style='width:24.35pt;height:10.9pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="309097,138633" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:rect id="Rectangle_x0020_9489" o:spid="_x0000_s1029" style='position:absolute;
    width:411100;height:184382;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
       margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
       line-height:107%'>with <o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><w:wrap type="none" anchorx="page"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="46" height="3" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:24.35pt;height:10.9pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>efavirenz, a component of Efaverinz,</p><p>emitracitabine</p><p>Tenofovir disporoxil fumarate Tablets.&nbsp; clinical outcome of this&nbsp; observed reduction</p><p>&nbsp;boceprevir trough concentrations has not been directly assessed.</p></td><td style="vertical-align:top"><p>of and The</p><p>of</p></td></tr><tr><td style="vertical-align:top"><p>Ledipasvir/Sofosbuvir</p><p>(90 mg/400 mg q.d.) +</p><p>Efavirenz/Emtricitabine/Tenofovir disoproxil</p><p>(600 mg/200 mg/245 mg q.d.)</p></td><td colspan="3" style="vertical-align:top"><p>Ledipasvir:</p><p>AUC: &darr; 34% (&darr; 41 to &darr; 25)</p><p>Cmax: &darr; 34% (&darr; 41 to &uarr; 25)</p><p>Cmin: &darr; 34% (&darr; 43 to &uarr; 24) Sofosbuvir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p></td><td colspan="2" style="vertical-align:top"><p>No dose adjustment is recommended. The</p><p>increased &nbsp;&nbsp;&nbsp; exposure &nbsp;&nbsp;&nbsp; of</p><p>tenofovir could potentiate adverse reactions associated with tenofovir disoproxil, including</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>GS-3310071:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Tenofovir:</p><p>AUC: &uarr; 98% (&uarr; 77 to &uarr; 123)</p><p>Cmax: &uarr; 79% (&uarr; 56 to &uarr; 104)</p><p>Cmin: &uarr; 163% (&uarr; 137 to &uarr; 197)</p></td><td style="vertical-align:top"><p>renal disorders. Renal function should closely monitored (see section 4.4).</p></td><td style="vertical-align:top"><p>be</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/Velpatasvir</p><p>(400 mg/100 mg q.d.) +</p><p>Efavirenz/Emtricitabine/Tenofovir disoproxil</p><p>(600 mg/200 mg/245 mg q.d.)</p></td><td style="vertical-align:top"><p>Sofosbuvir:</p><p>AUC: &harr;</p><p>Cmax: &uarr; 38% (&uarr; 14 to &uarr; 67) GS-3310071:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Velpatasvir:</p><p>AUC: &darr; 53% (&darr; 61 to &darr; 43)</p><p>Cmax: &darr; 47% (&darr; 57 to &darr; 36)</p><p>Cmin: &darr; 57% (&darr; 64 to &darr; 48) Efavirenz:</p></td><td colspan="2" style="vertical-align:top"><p>Concomitant</p><p>administration &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is expected to decrease plasma concentrations of velpatasvir and voxilaprevir. Co-</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Tenofovir:</p><p>AUC: &uarr; 81% (&uarr; 68 to &uarr; 94)</p><p>Cmax: &uarr; 77% (&uarr; 53 to &uarr; 104)</p><p>Cmin: &uarr; 121% (&uarr; 100 to &uarr; 143)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>administration</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is recommended section 4.4).</p></td><td rowspan="2" style="vertical-align:top"><p>of</p><p>with</p><p>not (see</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/Velpatasvir/Voxilaprevir&nbsp;</p><p>(400 mg/100 mg/100 mg q.d.) + Efavirenz/Emtricitabine/Tenofovir disoproxil</p><p>(600 mg/200 mg/245 mg q.d.)</p></td><td style="vertical-align:top"><p>Interaction &nbsp;&nbsp;&nbsp;&nbsp; only &nbsp;&nbsp;&nbsp; studied sofosbuvir/velpatasvir.</p><p>Expected:&nbsp;</p><p>Voxilaprevir:&darr;</p></td><td style="vertical-align:top"><p>with</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir</p><p>(400 mg q.d.) +</p><p>Efavirenz/Emtricitabine/Tenofovir disoproxil</p><p>(600 mg/200 mg/245 mg q.d.)</p></td><td style="vertical-align:top"><p>Sofosbuvir:</p><p>AUC: &harr;</p><p>Cmax: &darr; 19% (&darr; 40 to &uarr; 10) GS-3310071:</p><p>AUC: &harr;</p><p>Cmax: &darr; 23% (&darr; 30 to &uarr; 16) Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Emtricitabine:</p><p>AUC: &harr;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and sofosbuvir can be coadministered without dose adjustment.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Tenofovir:</p><p>AUC: &harr;</p><p>Cmax: &uarr; 25% (&uarr; 8 to &uarr; 45)</p><p>Cmin: &harr;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Simeprevir/Efavirenz</p><p>(150 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Simeprevir:</p><p>AUC: &darr; 71% (&darr; 67 to &darr; 74)</p><p>Cmax: &darr; 51% (&darr; 46 to &darr; 56)</p><p>Cmin: &darr; 91% (&darr; 88 to &darr; 92) Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>No effect (&harr;) equals a decrease in mean ratio estimate of &le; 20% or increase in mean ratio estimate of &le; 25%.</p><p>(CYP3A4 induction)</p></td><td rowspan="3" style="vertical-align:top"><p>Concomitant administration simeprevir</p><p>efavirenz, a component of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efaverinz,</p><p>emitracitabine</p><p>Tenofovir &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disporoxil fumarate</p><p>&nbsp;resulted in significantly&nbsp; decreased&nbsp; concentrations</p><p>simeprevir &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; due</p><p>CYP3A induction&nbsp; efavirenz, which&nbsp; result in loss</p><p>&nbsp;therapeutic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; effect</p><p>simeprevir. administration simeprevir</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is not</p></td><td rowspan="3" style="vertical-align:top"><p>of</p><p>with</p><p>and Tablets,</p><p>plasma of to by may of of</p><p>Coof with</p></td></tr><tr><td style="vertical-align:top"><p>Simeprevir/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied. Clinically significant interactions are not expected as simeprevir and</p><p>emtricitabine are eliminated via different pathways.</p></td></tr><tr><td style="vertical-align:top"><p>Simeprevir/Tenofovir disoproxil</p><p>(150 mg q.d./245 mg q.d.)</p></td><td style="vertical-align:top"><p>Simeprevir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cmin: &harr;</p><p>Tenofovir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>No effect (&harr;) equals a decrease in mean ratio estimate of &le; 20% or increase in mean ratio estimate of &le; 25%.</p></td><td style="vertical-align:top"><p>recommended.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Antibiotics&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin/Efavirenz</p><p>(500 mg b.i.d./400 mg q.d.)</p></td><td style="vertical-align:top"><p>Clarithromycin:</p><p>AUC: &darr; 39% (&darr; 30 to &darr; 46)</p><p>Cmax: &darr; 26% (&darr; 15 to &darr; 35)</p><p>Clarithromycin &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14hydroxymetabolite:</p><p>AUC: &uarr; 34% (&uarr; 18 to &uarr; 53) Cmax: &uarr; 49% (&uarr; 32 to &uarr; 69) Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &uarr; 11% (&uarr; 3 to &uarr; 19)</p><p>(CYP3A4 induction)</p><p>Rash developed in 46% of uninfected volunteers receiving efavirenz and clarithromycin.</p></td><td rowspan="3" style="vertical-align:top"><p>The clinical significance of these changes in clarithromycin plasma levels is not known.&nbsp;</p><p>Alternatives to clarithromycin (e.g. azithromycin) may be considered. Other macrolide antibiotics, such as erythromycin, have not been studied in&nbsp; combination with</p><p>&nbsp;Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets.</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Antimycobacterials&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Rifabutin/Efavirenz</p><p>(300 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Rifabutin:</p><p>AUC: &darr; 38% (&darr; 28 to &darr; 47)</p><p>Cmax: &darr; 32% (&darr; 15 to &darr; 46)</p><p>Cmin: &darr; 45% (&darr; 31 to &darr; 56) Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &darr; 12% (&darr; 24 to &uarr; 1)</p><p>(CYP3A4 induction)</p></td><td rowspan="3" style="vertical-align:top"><p>The daily dose of rifabutin should be increased by 50% when given with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. Consider doubling the rifabutin dose in regimens where rifabutin is given 2 or 3 times a week in combination with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. The clinical effect of this dose adjustment has not been adequately evaluated. Individual tolerability and virological response should be considered when making the dose adjustment (see section</p><p>5.2).</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin/Efavirenz</p><p>(600 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Efavirenz:</p><p>AUC: &darr; 26% (&darr; 15 to &darr; 36)</p><p>Cmax: &darr; 20% (&darr; 11 to &darr; 28)</p></td><td style="vertical-align:top"><p>When Efaverinz, emitracitabine and Tenofovir disporoxil</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cmin: &darr; 32% (&darr; 15 to &darr; 46)</p><p>(CYP3A4 and CYP2B6 induction)</p></td><td rowspan="3" style="vertical-align:top"><p>fumarate Tablets is taken with rifampicin in patients weighing 50 kg or greater, an additional</p><p>200 mg/day (800 mg total) of efavirenz may provide exposure similar to a daily efavirenz dose of 600 mg when taken without rifampicin. The clinical effect of this dose adjustment has not been adequately evaluated. Individual tolerability and virological response should be considered when making the dose adjustment (see section 5.2). No dose adjustment of rifampicin is recommended when given with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin/Tenofovir disoproxil</p><p>(600 mg q.d./245 mg q.d.)</p></td><td style="vertical-align:top"><p>Rifampicin:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Tenofovir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Antifungals&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole/Efavirenz</p><p>(200 mg b.i.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Itraconazole:</p><p>AUC: &darr; 39% (&darr; 21 to &darr; 53)</p></td><td style="vertical-align:top"><p>Since no dose recommendation can be</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cmax: &darr; 37% (&darr; 20 to &darr; 51)</p><p>Cmin: &darr; 44% (&darr; 27 to &darr; 58)</p><p>(decrease &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole</p><p>concentrations: CYP3A4 induction) Hydroxyitraconazole:</p><p>AUC: &darr; 37% (&darr; 14 to &darr; 55)</p><p>Cmax: &darr; 35% (&darr; 12 to &darr; 52)</p><p>Cmin: &darr; 43% (&darr; 18 to &darr; 60) Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p></td><td rowspan="3" style="vertical-align:top"><p>made &nbsp;&nbsp;&nbsp; for &nbsp;&nbsp; itraconazole</p><p>when &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; used &nbsp;&nbsp;&nbsp;&nbsp; <!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_84237"
   o:spid="_x0000_s1026" style='width:24.4pt;height:10.9pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="309646,138633" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:rect id="Rectangle_x0020_10033" o:spid="_x0000_s1027" style='position:absolute;
    width:411829;height:184382;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal align=left style='margin-top:0in;margin-right:0in;
       margin-bottom:8.0pt;margin-left:0in;text-align:left;text-indent:0in;
       line-height:107%'>with <o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><w:wrap type="none" anchorx="page"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="46" height="3" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1025" type="#_x0000_t75" style='width:24.4pt;height:10.9pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets, alternative antifungal treatment should considered.</p></td><td rowspan="3" style="vertical-align:top"><p>an</p><p>be</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Posaconazole/Efavirenz</p><p>(-/400 mg q.d.)</p></td><td style="vertical-align:top"><p>Posaconazole:</p><p>AUC: &darr; 50%</p><p>Cmax: &darr; 45%</p><p>(UDP-G induction)</p></td><td colspan="2" rowspan="3" style="vertical-align:top"><p>Concomitant use of posaconazole and</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be avoided unless the benefit to the patient outweighs the risk.</p></td></tr><tr><td style="vertical-align:top"><p>Posaconazole/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Posaconazole/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Voriconazole/Efavirenz</p><p>(200 mg b.i.d./400 mg q.d.)</p></td><td style="vertical-align:top"><p>Voriconazole:</p><p>AUC: &darr; 77% Cmax: &darr; 61% Efavirenz:</p><p>AUC: &uarr; 44%</p></td><td colspan="2" style="vertical-align:top"><p>Since Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is a fixed-dose combination</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Cmax: &uarr; 38%</p><p>(competitive inhibition of oxidative metabolism)</p><p>Co-administration of standard doses of efavirenz and voriconazole is contraindicated (see section 4.3).</p></td><td rowspan="3" style="vertical-align:top"><p>product, the dose of efavirenz cannot be altered; therefore,&nbsp; voriconazole and</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets must not be co-administered.</p></td></tr><tr><td style="vertical-align:top"><p>Voriconazole/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Voriconazole/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Antimalarials&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Artemether/Lumefantrine/Efavirenz (20/120 mg tablet, 6 doses of 4 tablets each over 3 days/600 mg q.d.)</p></td><td style="vertical-align:top"><p>Artemether:</p><p>AUC: &darr; 51%</p><p>Cmax: &darr; 21%&nbsp; Dihydroartemisinin metabolite):</p><p>AUC: &darr; 46%</p><p>Cmax: &darr; 38%&nbsp; Lumefantrine:</p><p>AUC: &darr; 21%</p><p>Cmax: &harr;</p><p>Efavirenz:</p><p>AUC: &darr; 17%</p><p>Cmax: &harr;</p><p>(CYP3A4 induction)</p></td><td style="vertical-align:top"><p>(active</p></td><td rowspan="3" style="vertical-align:top"><p>Since decreased concentrations of</p><p>artemether,</p><p>dihydroartemisinin, or lumefantrine may result</p><p>in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a &nbsp;&nbsp;&nbsp;&nbsp; decrease &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>antimalarial efficacy, caution is recommended when Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and artemether/lumefantrine</p><p>tablets are &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; coadministered.</p></td></tr><tr><td style="vertical-align:top"><p>Artemether/Lumefantrine/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Artemether/Lumefantrine/Tenofovir disoproxil</p></td><td colspan="2" style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Atovaquone &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; proguanil</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;Atovaquone:</p></td><td style="vertical-align:top"><p>Concomitant</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>hydrochloride/Efavirenz</p><p>(250/100 mg single dose/600 mg q.d.)</p></td><td style="vertical-align:top"><p>AUC: &darr; 75% (&darr; 62 to &darr; 84) Cmax: &darr; 44% (&darr; 20 to &darr; 61) Proguanil:</p><p>AUC: &darr; 43% (&darr; 7 to &darr; 65)</p><p>Cmax: &harr;</p></td><td rowspan="3" style="vertical-align:top"><p>administration &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>atovaquone/proguanil</p><p>with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be avoided.</p></td></tr><tr><td style="vertical-align:top"><p>Atovaquone &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; proguanil</p><p>hydrochloride/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Atovaquone &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; proguanil</p><p>hydrochloride/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ANTICONVULSANTS&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine/Efavirenz</p><p>(400 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Carbamazepine:</p><p>AUC: &darr; 27% (&darr; 20 to &darr; 33)</p><p>Cmax: &darr; 20% (&darr; 15 to &darr; 24)</p><p>Cmin: &darr; 35% (&darr; 24 to &darr; 44) Efavirenz:</p><p>AUC: &darr; 36% (&darr; 32 to &darr; 40)</p><p>Cmax: &darr; 21% (&darr; 15 to &darr; 26)</p><p>Cmin: &darr; 47% (&darr; 41 to &darr; 53)</p><p>(decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations:</p><p>CYP3A4 and CYP2B6 induction)</p><p>Co-administration of higher doses of either efavirenz or carbamazepine has not been studied.</p></td><td rowspan="3" style="vertical-align:top"><p>No dose recommendation can be made for the use of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets with carbamazepine. An alternative anticonvulsant should be considered.&nbsp; Carbamazepine plasma levels should be monitored periodically.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Phenytoin, Phenobarbital, and other anticonvulsants that are substrates of CYP isozymes</p></td><td style="vertical-align:top"><p>&nbsp;Interaction not studied with&nbsp; efavirenz, emtricitabine, or tenofovir disoproxil. There is a potential for reduction or increase in the plasma concentrations of phenytoin, phenobarbital and other</p><p>anticonvulsants that are substrates of CYP isozymes with efavirenz.</p></td><td style="vertical-align:top"><p>When Efaverinz, emitracitabine and&nbsp; Tenofovir disporoxil&nbsp; fumarate Tablets is coadministered with an&nbsp; anticonvulsant that is a substrate of CYP isozymes, periodic</p><p>monitoring &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>anticonvulsant levels should be conducted.</p></td></tr><tr><td style="vertical-align:top"><p>Valproic acid/Efavirenz</p><p>(250 mg b.i.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>No clinically significant effect on efavirenz pharmacokinetics. Limited data suggest there is no clinically significant effect on valproic acid pharmacokinetics.</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;Efaverinz, emitracitabine&nbsp; and Tenofovir disporoxil&nbsp; fumarate Tablets and&nbsp; valproic acid can be coadministered without dose adjustment. Patients should be monitored for seizure control.</p></td></tr><tr><td style="vertical-align:top"><p>Valproic acid/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Valproic acid/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Vigabatrin/Efavirenz</p><p>Gabapentin/Efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied. Clinically significant interactions are not expected since vigabatrin and gabapentin are exclusively eliminated unchanged in the urine and are unlikely to compete for the same metabolic enzymes and elimination pathways as efavirenz.</p></td><td style="vertical-align:top"><p>&nbsp;Efaverinz, emitracitabine&nbsp; and Tenofovir disporoxil&nbsp; fumarate Tablets and&nbsp; vigabatrin or gabapentin&nbsp; can be co-administered&nbsp; without dose adjustment.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Vigabatrin/Emtricitabine</p><p>Gabapentin/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vigabatrin/Tenofovir disoproxil</p><p>Gabapentin/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>ANTICOAGULANTS&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Warfarin/Efavirenz</p><p>Acenocoumarol/Efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied. Plasma concentrations and effects of warfarin or acenocoumarol are potentially increased or decreased by efavirenz.</p></td><td style="vertical-align:top"><p>Dose &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adjustment</p><p>warfarin</p><p>&nbsp;acenocoumarol may be&nbsp; required when administered</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets.</p></td><td style="vertical-align:top"><p>of or</p><p>cowith</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ANTIDEPRESSANTS&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Selective Serotonin Reuptake Inhibitors (SSRIs)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sertraline/Efavirenz</p><p>(50 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Sertraline:</p><p>AUC: &darr; 39% (&darr; 27 to &darr; 50)</p><p>Cmax: &darr; 29% (&darr; 15 to &darr; 40)</p><p>Cmin: &darr; 46% (&darr; 31 to &darr; 58) Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &uarr; 11% (&uarr; 6 to &uarr; 16)</p><p>Cmin: &harr;</p><p>(CYP3A4 induction)</p></td><td rowspan="3" style="vertical-align:top"><p>When co-administered with Efaverinz,</p><p>emitracitabine</p><p>Tenofovir disporoxil fumarate Tablets, sertraline dose increases should be guided by clinical response.</p></td><td rowspan="3" style="vertical-align:top"><p>and</p></td></tr><tr><td style="vertical-align:top"><p>Sertraline/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Sertraline/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Paroxetine/Efavirenz</p><p>(20 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Paroxetine:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Efavirenz:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p></td><td rowspan="3" style="vertical-align:top"><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and paroxetine can be coadministered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Paroxetine/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Paroxetine/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Fluoxetine/Efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied. Since fluoxetine shares a similar metabolic profile with paroxetine, i.e. a strong CYP2D6 inhibitory effect, a similar lack of interaction would be expected for fluoxetine.</p></td><td rowspan="3" style="vertical-align:top"><p>Efaverinz, emitracitabine&nbsp; and Tenofovir disporoxil fumarate Tablets and</p><p>&nbsp;fluoxetine can be coadministered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Fluoxetine/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Fluoxetine/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Norepinephrine and dopamine reuptake inhibitor&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bupropion/Efavirenz</p><p>[150 &nbsp;&nbsp;&nbsp;&nbsp; mg &nbsp;&nbsp;&nbsp;&nbsp; single &nbsp;&nbsp;&nbsp;&nbsp; dose &nbsp;&nbsp;&nbsp;&nbsp; (sustained</p><p>release)/600 mg q.d.]</p></td><td style="vertical-align:top"><p>Bupropion:</p><p>AUC: &darr; 55% (&darr; 48 to &darr; 62) Cmax: &darr; 34% (&darr; 21 to &darr; 47) Hydroxybupropion:</p><p>AUC: &harr;</p><p>Cmax: &uarr; 50% (&uarr; 20 to &uarr; 80)</p><p>(CYP2B6 induction)</p></td><td rowspan="2" style="vertical-align:top"><p>Increases in bupropion dosage should be guided by clinical response, but the maximum</p><p>recommended &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dose of</p><p>bupropion should not be exceeded. No dose adjustment is necessary</p></td></tr><tr><td style="vertical-align:top"><p>Bupropion/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Bupropion/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td style="vertical-align:top"><p>for efavirenz.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>CARDIOVASCULAR AGENTS&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Calcium Channel Blockers&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diltiazem/Efavirenz</p><p>(240 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Diltiazem:</p><p>AUC: &darr; 69% (&darr; 55 to &darr; 79)&nbsp;</p><p>Cmax: &darr; 60% (&darr; 50 to &darr; 68)&nbsp;</p><p>Cmin: &darr; 63% (&darr; 44 to &darr; 75) Desacetyl diltiazem:</p><p>AUC: &darr; 75% (&darr; 59 to &darr; 84)&nbsp;</p><p>Cmax: &darr; 64% (&darr; 57 to &darr; 69)&nbsp;</p><p>Cmin: &darr; 62% (&darr; 44 to &darr; 75)</p><p>N-monodesmethyl diltiazem:</p><p>AUC: &darr; 37% (&darr; 17 to &darr; 52)</p><p>Cmax: &darr; 28% (&darr; 7 to &darr; 44) Cmin: &darr; 37% (&darr; 17 to &darr; 52) Efavirenz:</p><p>AUC: &uarr; 11% (&uarr; 5 to &uarr; 18)</p><p>Cmax: &uarr; 16% (&uarr; 6 to &uarr; 26)&nbsp;</p><p>Cmin: &uarr; 13% (&uarr; 1 to &uarr; 26)</p><p>(CYP3A4 induction)</p><p>The &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; efavirenz</p><p>pharmacokinetic parameters is not considered clinically significant.</p></td><td rowspan="3" style="vertical-align:top"><p>Dose adjustments diltiazem when administered</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be guided by clinical response (refer to the Summary of Product</p><p>Characteristics diltiazem).</p><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>of co-</p><p>with</p><p>for</p></td></tr><tr><td style="vertical-align:top"><p>Diltiazem/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Diltiazem/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Verapamil, Felodipine, Nifedipine and</p><p>Nicardipine</p></td><td style="vertical-align:top"><p>&nbsp;Interaction not studied with efavirenz, emtricitabine, or tenofovir</p></td><td colspan="2" style="vertical-align:top"><p>Dose &nbsp;&nbsp;&nbsp;&nbsp; adjustments &nbsp;&nbsp;&nbsp;&nbsp; of</p><p>calcium channel blockers</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>disoproxil. When efavirenz is coadministered with a calcium channel blocker that is a substrate of the CYP3A4 enzyme, there is a potential for reduction in the plasma concentrations of the calcium channel blocker.</p></td><td style="vertical-align:top"><p>when with</p><p>&nbsp;emitracitabine&nbsp; Tenofovir</p><p>&nbsp;fumarate Tablets should&nbsp; be guided by clinical response (refer to the</p></td><td style="vertical-align:top"><p>co-administered Efaverinz,</p><p>disporoxil</p></td><td style="vertical-align:top"><p>and</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Summary &nbsp;&nbsp;&nbsp;&nbsp; of</p></td><td style="vertical-align:top"><p>Product</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Characteristics</p></td><td style="vertical-align:top"><p>for</p></td><td style="vertical-align:top"><p>the</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>calcium blocker).</p></td><td style="vertical-align:top"><p>channel</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>LIPID LOWERING MEDICINAL PRODUCTS&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>HMG Co-A Reductase Inhibitors&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin/Efavirenz</p><p>(10 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Atorvastatin:</p><p>AUC: &darr; 43% (&darr; 34 to &darr; 50)</p><p>Cmax: &darr; 12% (&darr; 1 to &darr; 26) 2-hydroxy atorvastatin:</p><p>AUC: &darr; 35% (&darr; 13 to &darr; 40)</p><p>Cmax: &darr; 13% (&darr; 0 to &darr; 23) 4-hydroxy atorvastatin:</p><p>AUC: &darr; 4% (&darr; 0 to &darr; 31)</p><p>Cmax: &darr; 47% (&darr; 9 to &darr; 51)</p><p>Total active HMG Co-A reductase inhibitors:&nbsp;</p><p>AUC: &darr; 34% (&darr; 21 to &darr; 41)</p><p>Cmax: &darr; 20% (&darr; 2 to &darr; 26)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" rowspan="2" style="vertical-align:top"><p>Cholesterol levels should be periodically monitored. Dosage</p><p>adjustments atorvastatin may required when</p><p>administered</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil&nbsp; fumarate Tablets (refer to the Summary of Product Characteristics atorvastatin).</p></td><td rowspan="2" style="vertical-align:bottom"><p>of</p><p>be</p><p>co-</p><p>with</p><p>for</p></td></tr><tr><td style="vertical-align:top"><p>Atorvastatin/Emtricitabine</p></td><td colspan="2" style="vertical-align:top"><p>Interaction not studied.</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Atorvastatin/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pravastatin/Efavirenz</p><p>(40 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Pravastatin:</p><p>AUC: &darr; 40% (&darr; 26 to &darr; 57)</p><p>Cmax: &darr; 18% (&darr; 59 to &uarr; 12)</p></td><td rowspan="3" style="vertical-align:top"><p>Cholesterol levels should be periodically monitored. Dosage</p><p>adjustments pravastatin may required when</p><p>administered</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (refer to the Summary of Product Characteristics pravastatin).</p></td><td rowspan="3" style="vertical-align:bottom"><p>of be co-</p><p>with</p><p>for</p></td></tr><tr><td style="vertical-align:top"><p>Pravastatin/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Pravastatin/Tenofovir disoproxil&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Simvastatin/Efavirenz</p><p>(40 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Simvastatin:</p><p>AUC: &darr; 69% (&darr; 62 to &darr; 73) Cmax: &darr; 76% (&darr; 63 to &darr; 79) Simvastatin acid:</p><p>AUC: &darr; 58% (&darr; 39 to &darr; 68)</p><p>Cmax: &darr; 51% (&darr; 32 to &darr; 58)</p><p>Total active HMG Co-A reductase inhibitors:</p><p>AUC: &darr; 60% (&darr; 52 to &darr; 68)</p><p>Cmax: &darr; 62% (&darr; 55 to &darr; 78)</p><p>(CYP3A4 induction)</p><p>Co-administration of efavirenz with atorvastatin, pravastatin, or simvastatin did not affect efavirenz</p></td><td style="vertical-align:top"><p>Cholesterol levels should be periodically monitored. Dosage</p><p>adjustments simvastatin may required when</p><p>&nbsp;administered</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (refer to the Summary of Product</p><p>&nbsp;Characteristics simvastatin).</p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>of</p><p>be</p><p>co-</p><p>with</p><p>for</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AUC or Cmax values.</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Simvastatin/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Simvastatin/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Rosuvastatin/Efavirenz</p></td><td style="vertical-align:top"><p>Interaction not studied. Rosuvastatin is largely excreted unchanged via the faeces, therefore interaction with efavirenz is not expected.</p></td><td rowspan="3" style="vertical-align:top"><p>Efaverinz, emitracitabine&nbsp; and Tenofovir disporoxil&nbsp; fumarate Tablets and rosuvastatin can be coadministered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Rosuvastatin/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Rosuvastatin/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>HORMONAL CONTRACEPTIVES&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Oral:</p><p>Ethinyloestradiol+Norgestimate/Efavirenz</p><p>(0.035 mg+0.25 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Ethinyloestradiol:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &darr; 8% (&uarr; 14 to &darr; 25)</p><p>Norelgestromin (active metabolite):</p><p>AUC: &darr; 64% (&darr; 62 to &darr; 67)</p><p>Cmax: &darr; 46% (&darr; 39 to &darr; 52)</p><p>Cmin: &darr; 82% (&darr; 79 to &darr; 85)</p><p>Levonorgestrel (active metabolite):</p><p>AUC: &darr; 83% (&darr; 79 to &darr; 87)</p><p>Cmax: &darr; 80% (&darr; 77 to &darr; 83)</p><p>Cmin: &darr; 86% (&darr; 80 to &darr; 90)</p><p>(induction of metabolism)</p><p>Efavirenz: no clinically significant interaction.</p><p>The clinical significance of these effects is not known.</p></td><td style="vertical-align:top"><p>A reliable method of barrier contraception must be used in addition to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hormonal contraceptives (see section 4.6).</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Ethinyloestradiol/Tenofovir disoproxil</p><p>(-/245 mg q.d.)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ethinyloestradiol:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Tenofovir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Norgestimate/Ethinyloestradiol/</p><p>Emtricitabine</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Injection:</p><p>Depomedroxyprogesterone</p><p>(DMPA)/Efavirenz</p><p>(150 mg IM single dose DMPA)</p></td><td style="vertical-align:top"><p>acetate</p></td><td style="vertical-align:top"><p>In a 3-month drug interaction study,&nbsp; no significant differences in MPA pharmacokinetic parameters were found between subjects receiving efavirenz-containing antiretroviral therapy and subjects receiving no antiretroviral therapy. Similar results were found by other investigators, although the MPA plasma levels were more variable in the second study. In both studies, plasma progesterone levels for subjects receiving efavirenz and DMPA remained low consistent with suppression of ovulation.</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;Because of the limited information available, a reliable method of barrier&nbsp; contraception must be&nbsp; used in addition to&nbsp; hormonal contraceptives&nbsp; (see section 4.6).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>DMPA/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>DMPA/Emtricitabine</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Implant:</p><p>Etonogestrel/Efavirenz</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied. Decreased exposure of etonogestrel may be</p></td><td style="vertical-align:top"><p>&nbsp;A reliable method of&nbsp; barrier contraception</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>expected (CYP3A4 induction). There have been occasional post-marketing reports of contraceptive failure with etonogestrel in efavirenz-exposed patients.</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;must be used in addition&nbsp; to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hormonal contraceptives&nbsp; section 4.6).</p></td><td rowspan="3" style="vertical-align:top"><p>(see</p></td></tr><tr><td style="vertical-align:top"><p>Etonogestrel/Tenofovir disoproxil</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Etonogestrel/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>IMMUNOSUPPRESSANTS&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immunosuppressants metabolised by CYP3A4 (e.g. cyclosporine, tacrolimus, sirolimus)/Efavirenz</p></td><td style="vertical-align:top"><p>&nbsp;Interaction not studied.</p><p>&nbsp;&darr; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exposure &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the immunosuppressant may be expected (CYP3A4 induction).</p><p>These immunosuppressants are not anticipated to impact exposure of efavirenz.</p></td><td rowspan="2" style="vertical-align:top"><p>Dose adjustments of the immunosuppressant may</p><p>&nbsp;be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; required.</p><p>monitoring</p><p>&nbsp;immunosuppressant</p><p>concentrations for at least two weeks (until stable concentrations reached) is recommended when starting or stopping treatment with Efaverinz, emitracitabine</p><p>Tenofovir disporoxil fumarate Tablets.</p></td><td rowspan="2" style="vertical-align:top"><p>Close of</p><p>are</p><p>and</p></td></tr><tr><td style="vertical-align:top"><p>Tacrolimus/Emtricitabine/Tenofovir disoproxil</p><p>(0.1 mg/kg q.d./200 mg/245 mg q.d.)</p></td><td style="vertical-align:top"><p>Tacrolimus:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>C24h: &harr;</p><p>Emtricitabine:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>C24h: &harr;</p><p>Tenofovir disoproxil:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>C24h: &harr;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>OPIOIDS&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Methadone/Efavirenz</p><p>(35-100 mg q.d./600 mg q.d.)</p></td><td style="vertical-align:top"><p>Methadone:</p><p>AUC: &darr; 52% (&darr; 33 to &darr; 66)</p><p>Cmax: &darr; 45% (&darr; 25 to &darr; 59)</p><p>(CYP3A4 induction)</p><p>In a study of HIV infected intravenous drug users, coadministration of efavirenz with methadone resulted in decreased plasma levels of methadone and signs of opiate withdrawal. The methadone dose was increased by a mean of 22% to alleviate withdrawal symptoms.</p></td><td rowspan="3" style="vertical-align:top"><p>Concomitant administration &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil&nbsp; fumarate Tablets should be avoided due to the risk for QTc prolongation</p><p>&nbsp;(see section 4.3).<strong> </strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Methadone/Tenofovir disoproxil</p><p>(40-110 mg q.d./245 mg q.d.)</p></td><td style="vertical-align:top"><p>Methadone:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p><p>Tenofovir:</p><p>AUC: &harr;</p><p>Cmax: &harr;</p><p>Cmin: &harr;</p></td></tr><tr><td style="vertical-align:top"><p>Methadone/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Buprenorphine/naloxone/Efavirenz</p></td><td style="vertical-align:top"><p>Buprenorphine:</p><p>AUC: &darr; 50%</p><p>Norbuprenorphine:</p><p>AUC: &darr; 71%</p></td><td style="vertical-align:top"><p>Despite the decrease in buprenorphine exposure, no patients exhibited withdrawal symptoms.</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Efavirenz:</p><p>No &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clinically &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; significant pharmacokinetic interaction.</p></td><td rowspan="3" style="vertical-align:top"><p>Dose &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adjustment &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>&nbsp;buprenorphine may not be necessary when coadministered with</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets.</p></td></tr><tr><td style="vertical-align:top"><p>Buprenorphine/naloxone/Emtricitabine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr><tr><td style="vertical-align:top"><p>Buprenorphine/naloxone/Tenofovir disoproxil&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p></td></tr></tbody></table><p><strong>1 The predominant circulating metabolite of sofosbuvir. </strong></p><p>Studies conducted with other medicinal products&nbsp;</p><p>There were no clinically significant pharmacokinetic interactions when efavirenz was administered with azithromycin, cetirizine, fosamprenavir/ritonavir, lorazepam, nelfinavir, zidovudine, aluminium/magnesium hydroxide antacids, famotidine or fluconazole. The potential for interactions with efavirenz and other azole antifungals, such as ketoconazole, has not been studied.</p><p>There were no clinically significant pharmacokinetic interactions when emtricitabine was administered with stavudine, zidovudine or famciclovir. There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with emtricitabine, nelfinavir or ribavirin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Women of childbearing potential (see below and section 5.3)&nbsp;</p><p>Pregnancy should be avoided in women receiving Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. Women of childbearing potential should undergo pregnancy testing before initiation of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets.</p><p>Contraception in males and females&nbsp;</p><p>Barrier contraception should always be used in combination with other methods of contraception (for example, oral or other hormonal contraceptives, see section 4.5) while on therapy with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. Because of the long halflife of efavirenz, use of adequate contraceptive measures for 12 weeks after discontinuation of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is recommended.&nbsp;</p><p>Pregnancy&nbsp;</p><p>Efavirenz: There have been seven retrospective reports of findings consistent with neural tube defects, including meningomyelocele, all in mothers exposed to efavirenz-containing regimens (excluding any efavirenz-containing fixed-dose combination tablets) in the first trimester. Two additional cases (1 prospective and 1 retrospective) including events consistent with neural tube defects have been reported with the fixed-dose combination tablet containing efavirenz, emtricitabine, and tenofovir disoproxil. A causal relationship of these events to the use of efavirenz has not been established, and the denominator is unknown. As neural tube defects occur within the first 4 weeks of foetal development (at which time neural tubes are sealed), this potential risk would concern women exposed to efavirenz during the first trimester of pregnancy.&nbsp; As of July 2013, the Antiretroviral Pregnancy Registry (APR) has received prospective reports of 904 pregnancies with first trimester exposure to efavirenz-containing regimens, resulting in 766 live births. One child was reported to have a neural tube defect, and the frequency and pattern of other birth defects were similar to those seen in children exposed to non-efavirenz-containing regimens, as well as those in HIV negative controls. The incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births.</p><p>Malformations have been observed in foetuses from efavirenz-treated monkeys (see section 5.3).&nbsp; Emtricitabine and tenofovir disoproxil: A moderate amount of data on pregnant women (between 300-1,000 pregnancy outcomes) indicates no malformations or foetal/neonatal toxicity associated with emtricitabine and tenofovir disoproxil. Animal studies on emtricitabine and tenofovir disoproxil do not indicate reproductive toxicity (see section 5.3).</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be used during pregnancy unless the clinical condition of the woman requires treatment with efavirenz/emtricitabine/tenofovir disoproxil.</p><p>Breast-feeding&nbsp;</p><p>Efavirenz, emtricitabine and tenofovir have been shown to be excreted in human milk. There is insufficient information on the effects of efavirenz, emtricitabine and tenofovir in newborns/infants. A risk to the infants cannot be excluded. Therefore Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should not be used during breast-feeding.</p><p>As a general rule, it is recommended that HIV infected women do not breast-feed their infants in order to avoid transmission of HIV to the infant.</p><p>Fertility&nbsp;</p><p>No human data on the effect of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets are available. Animal studies do not indicate harmful effects of efavirenz, emtricitabine or tenofovir disoproxil on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, dizziness has been reported during treatment with efavirenz, emtricitabine and tenofovir disoproxil. Efavirenz may also cause impaired concentration and/or somnolence. Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving and operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile&nbsp;</p><p>The combination of efavirenz, emtricitabine and tenofovir disoproxil has been studied in 460 patients either as the fixed-dose combination tablet Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (study AI266073) or as the component products (study GS-01-934). Adverse reactions were generally consistent with those seen in previous studies of the individual components. The most frequently reported adverse reactions considered possibly or probably related to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets among patients treated up to 48 weeks in study AI266073 were psychiatric disorders (16%), nervous system disorders (13%), and gastrointestinal disorders (7%).</p><p>Severe skin reactions such as Stevens-Johnson syndrome and erythema multiforme; neuropsychiatric adverse reactions (including severe depression, death by suicide, psychosis-like behaviour, seizures); severe hepatic events; pancreatitis and lactic acidosis (sometimes fatal) have been reported.</p><p>Rare events of renal impairment, renal failure and uncommon events of proximal renal tubulopathy (including Fanconi syndrome) sometimes leading to bone abnormalities (infrequently contributing to fractures) have also been reported. Monitoring of renal function is recommended for patients receiving Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (see section 4.4).</p><p>Discontinuation of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis (see section 4.4).</p><p>The administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets with food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 5.2).</p><p>Tabulated list of adverse reactions&nbsp;</p><p>The adverse reactions from clinical study and post-marketing experience with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and the individual components of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in antiretroviral combination therapy are listed in Table 2 below by body system organ class, frequency and the component(s) of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets to which the adverse reactions are attributable. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100) or rare (&ge; 1/10,000 to &lt; 1/1,000). Adverse reactions associated with the use of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets: Treatment-emergent adverse reactions considered possibly or probably related to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets reported in study AI266073 (over 48 weeks; n = 203), which have not been associated with one of the individual components of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets, include:</p><p>Common:&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - anorexia</p><p>Uncommon:&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - dry mouth</p><p>-&nbsp; incoherent speech - increased appetite</p><p>-&nbsp; libido decreased</p><p>-&nbsp; myalgia</p><p>Table 2: Adverse reactions associated with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets listed by the component(s) of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets to which the adverse reactions are attributable&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz&nbsp;</p></td><td style="vertical-align:top"><p>Emtricitabine&nbsp;</p></td><td style="vertical-align:top"><p>Tenofovir disoproxil&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Blood and lymphatic system disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>neutropenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaemia1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Immune system disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>allergic reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Metabolism and nutrition disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypophosphataemia2</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>hypertriglyceridaemia3</p></td><td style="vertical-align:top"><p>hyperglycaemia, hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hypercholesterolaemia3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hypokalaemia2</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>lactic acidosis</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Psychiatric disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>depression (severe in 1.6%)3, anxiety3, abnormal dreams3,</p><p>insomnia3</p></td><td style="vertical-align:top"><p>&nbsp;abnormal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dreams, insomnia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>suicide attempt3, suicide ideation3, psychosis3,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>mania3, paranoia3, hallucination3, euphoric mood3, affect lability3, confusional state3,</p><p>aggression3, catatonia3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>completed suicide3,4, delusion3,4, neurosis3,4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Nervous system disorders:&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>headache</p></td><td style="vertical-align:top"><p>dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>cerebellar coordination and &nbsp;&nbsp;&nbsp;&nbsp; balance</p><p>disturbances3,</p><p>somnolence (2.0%)3, headache (5.7%)3, disturbance in attention (3.6%)3, dizziness</p><p>(8.5%)3</p></td><td style="vertical-align:top"><p>dizziness</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>convulsions3, amnesia3, thinking abnormal3, ataxia3, coordination abnormal3, agitation3, tremor</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Eye disorders:&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>vision blurred</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Ear and labyrinth disorders:&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>tinnitus, vertigo</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td colspan="4" style="vertical-align:top"><p>Vascular disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>flushing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Gastrointestinal disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>diarrhoea, nausea</p></td><td style="vertical-align:top"><p>diarrhoea, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>diarrhoea, vomiting, abdominal pain, nausea</p></td><td style="vertical-align:top"><p>&nbsp;elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal</p><p>pain, dyspepsia</p></td><td style="vertical-align:top"><p>abdominal pain, abdominal distension, flatulence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pancreatitis</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Hepatobiliary disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>elevated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aspartate</p><p>aminotransferase (AST), elevated alanine aminotransferase (ALT),</p><p>elevated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gamma-</p><p>glutamyltransferase</p><p>(GGT)</p></td><td style="vertical-align:top"><p>&nbsp;elevated serum AST and/or elevated serum ALT,</p><p>hyperbilirubinaemia</p></td><td style="vertical-align:top"><p>increased transaminases</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>hepatitis acute</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>hepatic failure3,4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatic steatosis, hepatitis</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>rash &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (moderate-severe,</p><p>11.6%, all grades, 18%)3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>rash</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>pruritus</p></td><td style="vertical-align:top"><p>vesiculobullous &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Stevens-Johnson</p><p>syndrome, erythema multiforme3, severe rash</p><p>(&lt; 1%)</p></td><td style="vertical-align:top"><p>angioedema4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>photoallergic dermatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>angioedema</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>elevated creatine kinase</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>rhabdomyolysis2, muscular weakness2</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>osteomalacia (manifested as bone pain and infrequently contributing to fractures)2,4,</p><p>myopathy2</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>Renal and urinary disorders:&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased creatinine, proteinuria, proximal renal tubulopathy including</p><p>Fanconi syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>renal failure (acute and chronic), acute tubular</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>necrosis, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nephritis</p><p>(including acute interstitial nephritis)4, nephrogenic diabetes insipidus</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Reproductive system and breast disorders:&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>General disorders and administration site conditions:&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>asthenia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>fatigue</p></td><td style="vertical-align:top"><p>pain, asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1&nbsp; Anaemia was common and skin discolouration (increased pigmentation) was very common<strong> </strong>when emtricitabine was administered to paediatric patients.</p><p>2&nbsp; This adverse reaction may occur as a consequence of proximal renal tubulopathy. It is not considered to be causally associated with tenofovir disoproxil in the absence of this condition.</p><p>3&nbsp; See section 4.8 Description of selected adverse reactions for more details.</p><p>4&nbsp; This adverse reaction was identified through post-marketing surveillance for either efavirenz, emtricitabine or tenofovir disoproxil. The frequency category was estimated from a statistical calculation based on the total number of patients treated with efavirenz in clinical trials (n = 3,969) or exposed to emtricitabine in randomised controlled clinical trials (n = 1,563) or exposed to tenofovir disoproxil in randomised controlled clinical trials and the expanded access programme (n = 7,319).</p><p>Description of selected adverse reactions&nbsp;</p><p>Rash: In clinical trials of efavirenz, rashes were usually mild-to-moderate maculopapular skin eruptions that occurred within the first two weeks of initiating therapy with efavirenz. In most patients rash resolved with continuing therapy with efavirenz within one month. Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets can be reinitiated in patients interrupting therapy because of rash. Use of appropriate antihistamines and/or corticosteroids is recommended when Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is restarted.</p><p>Psychiatric symptoms: Patients with a history of psychiatric disorders appear to be at greater risk of serious psychiatric adverse reactions listed in the efavirenz column of Table 2.</p><p>Nervous system symptoms: Nervous system symptoms are common with efavirenz, one of the components of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. In clinical controlled studies of efavirenz, nervous system symptoms of moderate to severe intensity were experienced by 19% (severe 2%) of patients, and 2% of patients discontinued therapy due to such symptoms. They usually begin during the first one or two days of efavirenz therapy and generally resolve after the first two to four weeks. They may occur more frequently when Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is taken concomitantly with meals possibly due to increased efavirenz plasma levels (see section 5.2). Dosing at bedtime seems to improve the tolerability of these symptoms (see section 4.2).</p><p>Hepatic failure with efavirenz: Hepatic failure, including cases in patients with no pre-existing hepatic disease or other identifiable risk factors, as reported post-marketing, were sometimes characterised by a fulminant course, progressing in some cases to transplantation or death.</p><p>Renal impairment: As Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets may cause renal damage, monitoring of renal function is recommended (see sections 4.4 and 4.8 Summary of the safety profile). Proximal renal tubulopathy generally resolved or improved after tenofovir disoproxil discontinuation. However, in some patients, declines in creatinine clearance did not completely resolve despite tenofovir disoproxil discontinuation. Patients at risk of renal impairment (such as patients with baseline renal risk factors, advanced HIV disease, or patients receiving concomitant nephrotoxic medications) are at increased risk of experiencing incomplete recovery of renal function despite tenofovir disoproxil discontinuation (see section 4.4).</p><p>Interaction with didanosine: Co-administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5). Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported.</p><p>Metabolic parameters: Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).</p><p>Immune Reactivation Syndrome: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&#39; disease) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4).</p><p>Osteonecrosis: Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see section 4.4).</p><p>Paediatric population&nbsp;</p><p>Insufficient safety data are available for children below 18 years<strong> </strong>of age. Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is not recommended in this population (see section 4.2).</p><p>Other special populations&nbsp;</p><p>Elderly: Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets has not been studied in patients over the age of 65. Elderly patients are<strong> more </strong>likely to have decreased hepatic or renal function, therefore caution should be exercised when treating elderly patients with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (see section 4.2).</p><p>Patients with renal impairment: Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any patient with mild renal impairment treated with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (see sections 4.2, 4.4 and 5.2).</p><p>HIV/HBV or HCV co-infected patients: Only a limited number of patients were co-infected with HBV (n = 13) or HCV (n = 26) in study GS-01-934. The adverse reaction profile of efavirenz, emtricitabine and tenofovir disoproxil in patients co-infected with HIV/HBV or HIV/HCV was similar to that observed in patients infected with HIV without co-infection. However, as would be expected in this patient population, elevations in AST and ALT occurred more frequently than in the general HIV infected population.</p><p>Exacerbations of hepatitis after discontinuation of treatment: In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis may occur after discontinuation of treatment (see section 4.4<strong>). </strong></p><p>Reporting of suspected adverse reactions&nbsp;</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&nbsp;&nbsp;&nbsp; not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong>Saudi&nbsp; Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:512px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;<strong><em>o Other GCC States:</em></strong><br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some patients accidentally taking 600 mg efavirenz twice daily have reported increased nervous system symptoms. One patient experienced involuntary muscle contractions.</p><p>If overdose occurs, the patient must be monitored for evidence of toxicity (see section 4.8), and standard supportive treatment applied as necessary.</p><p>Administration of activated charcoal may be used to aid removal of unabsorbed efavirenz. There is no specific antidote for overdose with efavirenz. Since efavirenz is highly protein bound, dialysis is unlikely to remove significant quantities of it from blood.</p><p>Up to 30% of the emtricitabine dose and approximately 10% of the tenofovir dose can be removed by haemodialysis. It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiviral for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR06</p><p>Mechanism of action and pharmacodynamic effects&nbsp;</p><p>Efavirenz is an NNRTI of HIV-1. Efavirenz non-competitively inhibits HIV-1 reverse transcriptase (RT) and does not significantly inhibit human immunodeficiency virus-2 (HIV-2) RT or cellular deoxyribonucleic acid (DNA) polymerases (&alpha;, &beta;, &gamma;, and &delta;). Emtricitabine is a nucleoside analogue of cytidine. Tenofovir disoproxil is converted in vivo to tenofovir, a nucleoside monophosphate (nucleotide) analogue of adenosine monophosphate.</p><p>Emtricitabine and tenofovir are phosphorylated by cellular enzymes to form emtricitabine triphosphate and tenofovir diphosphate, respectively. In vitro studies have shown that both emtricitabine and tenofovir can be fully phosphorylated when combined together in cells.<strong> </strong>Emtricitabine triphosphate and tenofovir diphosphate competitively inhibit HIV-1 reverse<strong> </strong>transcriptase, resulting in DNA chain termination.</p><p>Both emtricitabine triphosphate and tenofovir diphosphate are weak inhibitors of mammalian DNA polymerases and there was no evidence of toxicity to mitochondria in vitro and in vivo.&nbsp;</p><p>Cardiac Electrophysiology&nbsp;</p><p>The effect of efavirenz on the QTc interval was evaluated in an open-label, positive and placebo controlled, fixed single sequence 3-period, 3-treatment crossover QT study in 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean Cmax of efavirenz in subjects with CYP2B6 *6/*6 genotype following the administration of 600 mg daily dose for 14 days was 2.25-fold the mean Cmax observed in subjects with CYP2B6 *1/*1 genotype. A positive relationship between efavirenz concentration and QTc prolongation was observed. Based on the concentration-QTc relationship, the mean QTc prolongation and its upper bound 90% confidence interval are 8.7 ms and 11.3 ms in subjects with CYP2B6*6/*6 genotype following the administration of 600 mg daily dose for 14 days (see section 4.5).&nbsp;</p><p>Antiviral activity in vitro&nbsp;</p><p>Efavirenz demonstrated antiviral activity against most non-clade B isolates (subtypes A, AE, AG, C, D, F, G, J, and N) but had reduced antiviral activity against group O viruses. Emtricitabine displayed antiviral activity against HIV-1 clades A, B, C, D, E, F, and G. Tenofovir displayed antiviral activity against HIV-1 clades A, B, C, D, E, F, G, and O. Both emtricitabine and tenofovir showed strain specific activity against HIV-2 and antiviral activity against HBV.</p><p>In combination studies evaluating the in vitro antiviral activity of efavirenz and emtricitabine together, efavirenz and tenofovir together, and emtricitabine and tenofovir together, additive to synergistic antiviral effects were observed.</p><p>Resistance&nbsp;</p><p>Resistance to efavirenz can be selected in vitro and resulted in single or multiple amino acid substitutions in HIV-1 RT, including L100I, V108I, V179D, and Y181C. K103N was the most frequently observed RT substitution in viral isolates from patients who<strong> </strong>experienced rebound in viral load during clinical studies of efavirenz. Substitutions at RT positions 98, 100, 101<strong>, 108, </strong>138, 188, 190 or 225 were also observed, but at lower frequencies, and often only in combination with K103N. Cross-resistance profiles for efavirenz, nevirapine and delavirdine in vitro demonstrated that the K103N substitution confers loss of susceptibility to all three NNRTIs.</p><p>The potential for cross-resistance between efavirenz and NRTIs is low because of the different binding sites on the target and mechanism of action. The potential for cross-resistance between efavirenz and PIs is low because of the different enzyme targets involved.</p><p>Resistance to emtricitabine or tenofovir has been seen in vitro and in some HIV-1 infected patients due to the development of an M184V or M184I substitution in RT with emtricitabine or a K65R substitution in RT with tenofovir. Emtricitabine-resistant viruses with the M184V/I mutation were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir and zidovudine. The K65R mutation can also be selected by abacavir or didanosine and results in reduced susceptibility to these agents plus lamivudine, emtricitabine and tenofovir. Tenofovir disoproxil should be avoided in patients with HIV-1 harbouring the K65R mutation. Both the K65R and M184V/I mutation remain fully susceptible to efavirenz. In addition, a K70E substitution in HIV-1 RT has been selected by tenofovir and results in low-level reduced susceptibility to abacavir, emtricitabine, lamivudine and tenofovir.</p><p>Patients with HIV-1 expressing three or more thymidine analogue associated mutations (TAMs) that included either an M41L or an L210W substitution in RT showed reduced susceptibility to tenofovir disoproxil.</p><p>In vivo resistance (antiretroviral-na&iuml;ve patients): In a 144-week open-label randomised clinical study (GS-01-934) in antiretroviral-na&iuml;ve patients, where efavirenz, emtricitabine and tenofovir disoproxil were used as individual formulations (or as efavirenz and the fixed combination of emtricitabine and tenofovir disoproxil (Truvada) from week 96 to 144), genotyping was performed on plasma HIV-1 isolates from all patients with confirmed HIV RNA &gt; 400 copies/ml at week 144 or early study drug discontinuation (see section on Clinical experience). As of week 144:</p><p>&bull;&nbsp; The M184V/I mutation developed in 2/19 (10.5%) isolates analysed from patients in the efavirenz + emtricitabine + tenofovir disoproxil group and in 10/29 (34.5%) isolates<strong> </strong>analysed from the efavirenz + lamivudine/zidovudine group (p-value &lt; 0.05, Fisher&#39;s Exact test comparing the emtricitabine + tenofovir disoproxil group to the lamivudine/zidovudine group among all subjects).</p><p>&bull;&nbsp; No virus analysed contained the K65R or K70E mutation.</p><p>&bull;&nbsp; Genotypic resistance to efavirenz, predominantly the K103N mutation, developed in virus from 13/19 (68%) patients in the efavirenz + emtricitabine + tenofovir disoproxil group and in virus from 21/29 (72%) patients in the efavirenz + lamivudine/zidovudine group. A summary of resistance mutation development is shown in Table 3.</p><p>Table 3: Development of resistance in study GS-01-934 through week 144&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Efavirenz+&nbsp; emtricitabine+&nbsp; tenofovir disoproxil </strong></p><p><strong>(N=244)&nbsp; </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Efavirenz+lamivudine/zidovudine </strong></p><p><strong>(N=243)&nbsp; </strong></p></td></tr><tr><td style="vertical-align:top"><p>Resistance analysis by week 144</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>31</p></td></tr><tr><td style="vertical-align:top"><p>On-therapy genotypes</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>(100%)</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>(100%)</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz resistance1</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>(68%)</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>(72%)</p></td></tr><tr><td style="vertical-align:top"><p>K103N</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>(42%)</p></td><td style="vertical-align:top"><p>18*</p></td><td style="vertical-align:top"><p>(62%)</p></td></tr><tr><td style="vertical-align:top"><p>K101E</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>(16%)</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>(10%)</p></td></tr><tr><td style="vertical-align:top"><p>G190A/S</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>(10.5%)</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>(14%)</p></td></tr><tr><td style="vertical-align:top"><p>Y188C/H</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>(5%)</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>(7%)</p></td></tr><tr><td style="vertical-align:top"><p>V108I</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>(5%)</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>(3%)</p></td></tr><tr><td style="vertical-align:top"><p>P225H</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>(7%)</p></td></tr><tr><td style="vertical-align:top"><p>M184V/I</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>(10.5%)</p></td><td style="vertical-align:top"><p>10*</p></td><td style="vertical-align:top"><p>(34.5%)</p></td></tr><tr><td style="vertical-align:top"><p>K65R</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>K70E</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>TAMs2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>(7%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>* p-value &lt; 0.05, Fisher&#39;s Exact test comparing efavirenz + emtricitabine + tenofovir disoproxil group to efavirenz + lamivudine/zidovudine group among all patients.</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>1 Other efavirenz resistance mutations included A98G (n=1), K103E (n=1), V179D (n=1), and M230L (n=1).</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>2 Thymidine analogue associated mutations included D67N (n=1) and K70R (n=1).</p></td></tr></tbody></table><p>In the open-label extended phase of study GS-01-934, where patients received Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets on an empty stomach, 3 additional cases of resistance were seen. All 3 subjects had received a fixed dose combination of lamivudine and zidovudine (Combivir) and efavirenz for 144 weeks and then switched to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets. Two subjects with confirmed virologic rebound developed NNRTI resistance-associated substitutions to efavirenz including K103N, V106V/I/M and Y188Y/C reverse transcriptase substitutions at week 240 (96 weeks on Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets) and week 204 (60 weeks on Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets). A third subject had pre-existing NNRTI resistance-associated substitutions to efavirenz and the M184V reverse transcriptase resistance-associated substitution to emtricitabine at entry into the Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets extension phase and experienced a suboptimal virologic response, and developed K65K/R, S68N and K70K/E NRTI resistance-associated substitutions at week 180 (36 weeks on Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets).</p><p>Please refer to the Summary of Product Characteristics for the individual components for additional information regarding in vivo resistance with these medicinal products.</p><p>Clinical efficacy and safety&nbsp;</p><p>In a 144-week open-label randomised clinical study (GS-01-934) antiretroviral treatment-na&iuml;ve HIV-1 infected patients received either a once-daily regimen of efavirenz, emtricitabine and tenofovir disoproxil or a fixed combination of lamivudine and zidovudine (Combivir) administered twice daily and efavirenz once daily (please refer to the Summary of Product Characteristics for Truvada). Patients who completed 144 weeks of treatment with either treatment arm in study GS-01-934 were given the option to continue in an open-label extended phase of the study with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets on an empty stomach<strong>. </strong>Data are available from 286 patients<strong> </strong>who switched to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets: 160 had previously received efavirenz, emtricitabine and tenofovir disoproxil, and 126 had previously received Combivir and efavirenz. High rates of virologic suppression were maintained by subjects from both initial treatment groups who then received Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in the open-label extended phase of the study. After 96 weeks of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets treatment, HIV-1 RNA plasma concentrations remained &lt; 50 copies/ml in 82% of patients and &lt; 400 copies/ml in 85% of patients (intention to treat analysis (ITT), missing=failure).</p><p>Study AI266073 was a 48-week open-label randomised clinical study in HIV infected patients comparing the efficacy of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets to antiretroviral therapy consisting of at least two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) with a protease inhibitor or non-nucleoside reverse transcriptase inhibitor; however not a regimen containing all Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets components (efavirenz, emtricitabine and tenofovir disoproxil). Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets was administered on an empty stomach (see section 4.2). Patients had never experienced virological failure on a previous antiretroviral therapy, had no known HIV-1 mutations that confer resistance to any of the three components within Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets, and had been virologically suppressed for at least three months at baseline. Patients either changed to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (N=203) or continued on their original antiretroviral treatment regimen (N=97). Forty-eight week data showed that high levels of virologic suppression, comparable to the original treatment regimen, were maintained in patients who were randomised to change to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets (see Table 4).</p><p>Table 4: 48-week efficacy data from study AI266073 in which Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets was administered to virologically suppressed patients on combination antiretroviral therapy<strong>&nbsp; </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Treatment group&nbsp; </strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Endpoint&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Efaverinz, emitracitabine and Tenofovir disporoxil </strong></p><p><strong>fumarate &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablets</strong></p><p><strong>(N=203)&nbsp; n/N (%)&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Stayed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on </strong></p><p><strong>&nbsp;treatment </strong></p><p><strong>(N=97)&nbsp;&nbsp; n/N (%)&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>original regimen </strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;Difference between emitracitabine and </strong></p><p><strong>disporoxil fumarate Tablets and original treatment </strong></p><p><strong>(95%CI)&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Efaverinz, </strong></p><p><strong>Tenofovir </strong></p><p><strong>regimen </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>patients with HIV-1 R</p></td><td style="vertical-align:top"><p>NA &lt; 50 copies/m</p></td><td style="vertical-align:top"><p>l&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PVR (KM)</p></td><td style="vertical-align:top"><p>94.5%</p></td><td style="vertical-align:top"><p>85.5%</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>8.9% (-7.7% to 25.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>M=Excluded</p></td><td style="vertical-align:top"><p>179/181 (98.9%)</p></td><td style="vertical-align:top"><p>85/87 (97.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.2% (-2.3% to 6.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>M=Failure</p></td><td style="vertical-align:top"><p>179/203 (88.2%)</p></td><td style="vertical-align:top"><p>85/97 (87.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.5% (-7.0% to 9.3%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Modified LOCF</p></td><td style="vertical-align:top"><p>190/203 (93.6%)</p></td><td style="vertical-align:top"><p>94/97 (96.9%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>-3.3 (-8.3% to 2.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>patients with HIV-1 RNA &lt; 200 copies/ml&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PVR (KM)</p></td><td style="vertical-align:top"><p>98.4%</p></td><td colspan="2" style="vertical-align:top"><p>98.9%</p></td><td colspan="2" style="vertical-align:top"><p>-0.5% (-3.2% to 2.2%)</p></td></tr><tr><td style="vertical-align:top"><p>M=Excluded</p></td><td style="vertical-align:top"><p>181/181 (100%)</p></td><td colspan="2" style="vertical-align:top"><p>87/87 (100%)</p></td><td colspan="2" style="vertical-align:top"><p>0% (-2.4% to 4.2%)</p></td></tr><tr><td style="vertical-align:top"><p>M=Failure</p></td><td style="vertical-align:top"><p>181/203 (89.2%)</p></td><td colspan="2" style="vertical-align:top"><p>87/97 (89.7%)</p></td><td colspan="2" style="vertical-align:top"><p>-0.5% (-7.6% to 7.9%)</p></td></tr></tbody></table><p>PVR (KM): Pure virologic response assessed using the Kaplan Meier (KM) method</p><p>M: Missing</p><p>Modified LOCF: Post-hoc analysis where patients who failed virologically or discontinued for adverse events were treated as failures; for other drop-outs, the LOCF (last observation carried forward) method was applied</p><p>When the two strata were analysed separately, response rates in the stratum with prior PItreatment were numerically lower for patients switched to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets [92.4% versus 94.0% for the PVR (sensitivity analysis) for Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and SBR patients respectively; a difference (95%CI) of -1.6% (-10.0%, 6.7%). In the prior-NNRTI stratum, response rates were 98.9% vs 97.4% for Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets and SBR patients respectively; a difference (95%CI) of 1.4% (-4.0%, 6.9%)]. A similar trend was observed in a sub-group analysis of treatment-experienced patients with baseline HIV-1 RNA &lt; 75 copies/ml from a retrospective cohort study (data collected over 20 months, see Table 5).</p><p>Table 5: Maintenance of pure virologic response (Kaplan Meier % (Standard Error) [95%CI]) at week 48 for treatment-experienced patients with baseline HIV-1 RNA &lt; 75 copies/ml who had therapy switched to Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets according to the type of prior antiretroviral regimen (Kaiser Permanente patient database)&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Prior </strong></p></td><td style="vertical-align:top"><p><strong>Efaverinz, </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>emitracitabine </strong></p></td><td style="vertical-align:top"><p><strong>and</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Tenofovir </strong></p></td><td style="vertical-align:top"><p><strong>disporoxil </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>fumarate components&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Tablets</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;Prior NNRTI-based regimen&nbsp; </strong></p><p><strong>(N=104)&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Prior PI-based regimen&nbsp; </strong></p><p><strong>(N=34)&nbsp; </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>(N=299)&nbsp; </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>98.9% (0.6%)</p><p>[96.8%, 99.7%]</p></td><td style="vertical-align:top"><p>98.0% (1.4%)</p><p>[92.3%, 99.5%]</p></td><td style="vertical-align:top"><p>93.4% (4.5%)</p><p>[76.2%, 98.3%]</p></td></tr></tbody></table><p>No data are currently available from clinical studies with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in treatment-na&iuml;ve patients or in heavily pretreated patients. There is no clinical experience with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in patients who are experiencing virological failure in a first-line antiretroviral treatment regimen or in combination with other antiretroviral agents.</p><p>Patients coinfected with HIV and HBV&nbsp;</p><p>Limited clinical experience in patients co-infected with HIV and HBV suggests that treatment with emtricitabine or tenofovir disoproxil in antiretroviral combination therapy to control HIV infection also results in a reduction in HBV DNA (3 log10 reduction or 4 to 5 log10 reduction, respectively) (see section 4.4).</p><p>Paediatric population&nbsp;</p><p>The safety and efficacy of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in children under the age of 18 years have not been established<strong>. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The separate pharmaceutical forms of efavirenz, emtricitabine and tenofovir disoproxil were used to determine the pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil, administered separately in HIV infected patients. The bioequivalence of one Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets film-coated tablet with one efavirenz 600 mg film-coated tablet plus one emtricitabine 200 mg hard capsule plus one tenofovir disoproxil 245 mg film-coated tablet (equivalent to 300 mg tenofovir disoproxil fumarate) administered together, was established following single dose administration to fasting healthy subjects in study GS-US-177-0105 (see Table 6).</p><p>Table 6: Summary of pharmacokinetic data from study GS-US-177-0105&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Efavirenz&nbsp; </strong></p><p><strong>(n=45)&nbsp; </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Emtricitabine&nbsp; </strong></p><p><strong>(n=45)&nbsp; </strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Tenofovir disoproxil&nbsp; </strong></p><p><strong>(n=45)&nbsp; </strong></p></td></tr><tr><td style="vertical-align:bottom"><p>Parameters&nbsp;</p></td><td style="vertical-align:bottom"><p>Test&nbsp;</p></td><td style="vertical-align:bottom"><p>Reference&nbsp;</p></td><td style="vertical-align:top"><p>GMR (%)</p><p>(90%CI)&nbsp;</p></td><td style="vertical-align:bottom"><p>Test&nbsp;</p></td><td style="vertical-align:bottom"><p>Reference</p></td><td style="vertical-align:top"><p>GMR (%)</p><p>(90%CI)&nbsp;</p></td><td style="vertical-align:bottom"><p>Test&nbsp;</p></td><td style="vertical-align:bottom"><p>Reference</p></td><td style="vertical-align:top"><p>GMR (%)</p><p>(90%CI)&nbsp;</p></td></tr><tr><td><p>Cmax</p><p>(ng/ml)&nbsp;</p></td><td><p>2,264.3</p><p>(26.8)</p></td><td><p>2,308.6</p><p>(30.3)</p></td><td style="vertical-align:top"><p>98.79</p><p>(92.28,</p><p>105.76)</p></td><td><p>2,130.6</p><p>(25.3)</p></td><td><p>2,384.4</p><p>(20.4)</p></td><td style="vertical-align:top"><p>88.84</p><p>(84.02,</p><p>93.94)</p></td><td><p>325.1</p><p>(34.2)</p></td><td><p>352.9</p><p>(29.6)</p></td><td style="vertical-align:top"><p>91.46</p><p>(84.64,</p><p>98.83)</p></td></tr><tr><td><p>AUC0-last</p><p>(ng∙h/ml)&nbsp;</p></td><td><p>125,623.6</p><p>(25.7)</p></td><td><p>132,795.7</p><p>(27.0)</p></td><td style="vertical-align:top"><p>95.84</p><p>(90.73,</p><p>101.23)</p></td><td><p>10,682.6</p><p>(18.1)</p></td><td><p>10,874.4</p><p>(14.9)</p></td><td style="vertical-align:top"><p>97.98</p><p>(94.90,</p><p>101.16)</p></td><td><p>1,948.8</p><p>(32.9)</p></td><td><p>1,969.0</p><p>(32.8)</p></td><td style="vertical-align:top"><p>99.29</p><p>(91.02,</p><p>108.32)</p></td></tr><tr><td><p>AUCinf</p><p>(ng∙h/ml)&nbsp;</p></td><td><p>146,074.9</p><p>(33.1)</p></td><td><p>155,518.6</p><p>(34.6)</p></td><td style="vertical-align:top"><p>95.87</p><p>(89.63,</p><p>102.55)</p></td><td><p>10,854.9</p><p>(17.9)</p></td><td><p>11,054.3</p><p>(14.9)</p></td><td style="vertical-align:top"><p>97.96</p><p>(94.86,</p><p>101.16)</p></td><td><p>2,314.0</p><p>(29.2)</p></td><td><p>2,319.4</p><p>(30.3)</p></td><td style="vertical-align:top"><p>100.45</p><p>(93.22,</p><p>108.23)</p></td></tr><tr><td style="vertical-align:top"><p>T1/2</p><p>(h)&nbsp;</p></td><td style="vertical-align:top"><p>180.6&nbsp;</p><p>(45.3)</p></td><td style="vertical-align:top"><p>182.5&nbsp;</p><p>(38.3)</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>14.5&nbsp;</p><p>(53.8)</p></td><td style="vertical-align:top"><p>14.6&nbsp;</p><p>(47.8)</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>18.9&nbsp;</p><p>(20.8)</p></td><td style="vertical-align:top"><p>17.8&nbsp;</p><p>(22.6)</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr></tbody></table><p>Test: single fixed-dose combination tablet taken under fasted conditions.</p><p>Reference: single dose of a 600 mg efavirenz tablet, 200 mg emtricitabine capsule and 300 mg tenofovir disoproxil tablet taken under fasted conditions.</p><p>Values for Test and Reference are mean (% coefficient of variation).</p><p>GMR=geometric least-squares mean ratio, CI=confidence interval</p><p>Absorption&nbsp;</p><p>In HIV infected patients, peak efavirenz plasma concentrations were attained by 5 hours and steady-state concentrations reached in 6 to 7 days. In 35 patients receiving efavirenz 600 mg once daily, steady-state peak concentration (Cmax) was 12.9 &plusmn; 3.7 &micro;M (29%) [mean &plusmn; standard deviation (S.D.) (coefficient of variation (%CV))], steady-state Cmin was 5.6 &plusmn; 3.2 &micro;M (57%), and AUC was 184 &plusmn; 73 &micro;M&bull;h (40%).</p><p>Emtricitabine is rapidly absorbed with peak plasma concentrations occurring at 1 to 2 hours postdose. Following multiple dose oral administration of emtricitabine to 20 HIV infected patients, steady-state Cmax was 1.8 &plusmn; 0.7 &micro;g/ml (mean &plusmn; S.D.) (39%CV), steady-state Cmin was 0.09 &plusmn;</p><p>0.07 &micro;g/ml (80%) and the AUC was 10.0 &plusmn; 3.1 &micro;g&bull;h/ml (31%) over a 24 hour dosing interval.</p><p>Following oral administration of a single 300 mg dose of tenofovir disoproxil to HIV-1 infected<strong> </strong>patients in the fasted state, maximum tenofovir concentrations were achieved within one hour and the Cmax and AUC (mean &plusmn; S.D.) (%CV) values were 296 &plusmn; 90 ng/ml (30%) and 2,287 &plusmn; 685 ng&bull;h/ml (30%), respectively. The oral bioavailability of tenofovir from tenofovir disoproxil in fasted patients was approximately 25%.</p><p>Effect of food&nbsp;</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets has not been evaluated in the presence of food.</p><p>Administration of efavirenz capsules with a high fat meal increased the mean AUC and Cmax of efavirenz by 28% and 79%, respectively, compared to administration in a fasted state. Compared to fasted administration, dosing of tenofovir disoproxil and emtricitabine in combination with either a high fat meal or a light meal increased the mean AUC of tenofovir by 43.6% and 40.5%, and Cmax by 16% and 13.5%, respectively without affecting emtricitabine exposures.</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is recommended for administration on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8). It is anticipated that tenofovir exposure (AUC) will be approximately 30% lower following administration of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets on an empty stomach as compared to the individual component tenofovir disoproxil when taken with food (see section</p><p>5.1).</p><p>Distribution&nbsp;</p><p>Efavirenz is highly bound (&gt; 99%) to human plasma proteins, predominantly albumin.</p><p>In vitro binding of emtricitabine to human plasma proteins is &lt; 4% and independent of concentrations over the range of 0.02 to 200 &micro;g/ml. Following intravenous administration the volume of distribution of emtricitabine was approximately 1.4 l/kg. After oral administration, emtricitabine is widely distributed throughout the body. The mean plasma to blood concentration ratio was approximately 1.0 and the mean semen to plasma concentration ratio was approximately 4.0.</p><p>In vitro binding of tenofovir to human plasma or serum protein is &lt; 0.7% and 7.2%, respectively over the tenofovir concentration range 0.01 to 25 &micro;g/ml. Following intravenous administration the volume of distribution of tenofovir<strong> </strong>was approximately 800 ml/kg. After oral administration, tenofovir is widely distributed throughout the body.<strong> </strong></p><p>Biotransformation&nbsp;</p><p>Studies in humans and in vitro studies using human liver microsomes have demonstrated that efavirenz is principally metabolised by the CYP system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1. The in vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism and that it inhibits CYP isozymes 2C9, 2C19, and 3A4. In in vitro studies efavirenz did not inhibit CYP2E1 and inhibited CYP2D6 and CYP1A2 only at concentrations well above those achieved clinically.</p><p>Efavirenz plasma exposure may be increased in patients with homozygous G516T genetic variant of the CYP2B6 isozyme. The clinical implications of such an association are unknown; however, the potential for an increased frequency and severity of efavirenz-associated adverse events cannot be excluded.</p><p>Efavirenz has been shown to induce CYP3A4 and CYP2B6, resulting in the induction of its own metabolism, which may be clinically relevant in some patients. In uninfected volunteers, multiple doses of 200 to 400 mg per day for 10 days resulted in a lower than predicted extent of accumulation (22 to 42% lower) and a shorter terminal half-life of 40 to 55 hours (single dose half-life 52 to 76 hours). Efavirenz has also been shown to induce UGT1A1. Exposures of raltegravir (a UGT1A1 substrate) are reduced in the presence of efavirenz (see section 4.5, Table 1). Although in vitro data suggest that efavirenz inhibits CYP2C9 and CYP2C19, there have been contradictory reports of both increased and decreased exposures to substrates of these enzymes when co-administered with efavirenz in vivo. The net effect of co-administration is not clear.</p><p>There is limited metabolism of emtricitabine. The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3&#39;-sulphoxide diastereomers<strong> </strong>(approximately 9% of dose) and conjugation with glucuronic acid to form 2&#39;-O-glucuronide (approximately 4% of dose). In vitro studies have determined that neither tenofovir disoproxil nor tenofovir are substrates for the CYP enzymes. Neither emtricitabine nor tenofovir inhibited in vitro drug metabolism mediated by any of the major human CYP isoforms involved in drug<strong> </strong>biotransformation. Also, emtricitabine did not inhibit uridine 5&#39;-diphosphoglucuronyl transferase, the enzyme responsible for glucuronidation.<strong> </strong></p><p>Elimination&nbsp;</p><p>Efavirenz has a relatively long terminal half-life of at least 52 hours after single doses (see also data from bioequivalence study described above) and 40 to 55 hours after multiple doses. Approximately 14 to 34% of a radiolabelled dose of efavirenz was recovered in the urine and less than 1% of the dose was excreted in urine as unchanged efavirenz.</p><p>Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours. Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites. The systemic clearance of emtricitabine averaged 307 ml/min.</p><p>Following oral administration, the elimination half-life of tenofovir is approximately 12 to 18 hours. Tenofovir is primarily excreted by the kidneys by both filtration and an active tubular transport system with approximately 70 to 80% of the dose excreted unchanged in urine following intravenous administration. The apparent clearance of tenofovir averaged approximately 307 ml/min. Renal clearance has been estimated to be approximately 210 ml/min, which is in excess of the glomerular filtration rate. This indicates that active tubular secretion is an important part of the elimination of tenofovir.</p><p>Pharmacokinetics in special populations&nbsp;</p><p>Age&nbsp;</p><p>Pharmacokinetic studies have not been performed with efavirenz, emtricitabine or tenofovir in elderly patients (over 65 years of age).</p><p>Gender&nbsp;</p><p>The pharmacokinetics of emtricitabine and tenofovir are similar in male and female patients. Limited data suggest that females may have higher exposure to efavirenz but they do not appear to be less tolerant of efavirenz.</p><p>Ethnicity&nbsp;</p><p>Limited data suggest that Asian and Pacific Island patients may have higher exposure to efavirenz but they do not appear to be less tolerant of efavirenz.</p><p>Paediatric population&nbsp;</p><p>Pharmacokinetic studies have not been performed with Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets in infants and children under 18 years of age (see section 4.2).</p><p>Renal impairment&nbsp;</p><p>The pharmacokinetics of efavirenz, emtricitabine and tenofovir disoproxil after co-administration of the separate pharmaceutical forms or as Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets have not been studied in HIV infected patients with renal impairment.</p><p>Pharmacokinetic parameters were determined following administration of single doses of the individual preparations of emtricitabine 200 mg or tenofovir disoproxil 245 mg to non-HIV infected patients with varying degrees of renal impairment. The degree of renal impairment was defined according to baseline creatinine clearance (normal renal function when creatinine clearance &gt; 80 ml/min; mild impairment with creatinine clearance=50 to 79 ml/min; moderate impairment with creatinine clearance=30 to 49 ml/min and severe impairment with creatinine clearance=10 to 29 ml/min).</p><p>The mean (%CV) emtricitabine exposure increased from 12 &micro;g&bull;h/ml (25%) in subjects with normal renal function to 20 &micro;g&bull;h/ml (6%), 25 &micro;g&bull;h/ml (23%) and 34 &micro;g&bull;h/ml (6%) in patients with mild, moderate and severe renal impairment, respectively.</p><p>The mean (%CV) tenofovir exposure increased from 2,185 ng&bull;h/ml (12%) in patients with normal renal function, to 3,064 ng&bull;h/ml (30%), 6,009 ng&bull;h/ml (42%) and 15,985 ng&bull;h/ml (45%) in patients with mild, moderate and severe renal impairment, respectively.</p><p>In patients with end-stage renal disease (ESRD) requiring haemodialysis, between dialysis drug exposures substantially increased over 72 hours to 53 &micro;g&bull;h/ml (19%) of emtricitabine, and over 48 hours to 42,857 ng&bull;h/ml (29%) of tenofovir.</p><p>The pharmacokinetics of efavirenz have not been studied in patients with renal impairment. However, less than 1% of an efavirenz dose is excreted unchanged in the urine, so the impact of renal impairment on exposure to efavirenz is likely to be minimal.</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets is not recommended for patients with moderate or severe renal impairment (creatinine clearance &lt; 50 ml/min). Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and</p><p>4.4).</p><p>Hepatic impairment&nbsp;</p><p>The pharmacokinetics of Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets have not been studied in HIV infected patients with hepatic impairment. Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets should be administered with caution to patients with mild hepatic impairment (see sections 4.3 and 4.4).</p><p>Efaverinz, emitracitabine and Tenofovir disporoxil fumarate Tablets must not be used in patients with severe hepatic impairment (see section 4.3) and is not recommended for patients with moderate hepatic impairment. In a single-dose study of efavirenz, half-life was doubled in the single patient with severe hepatic impairment (Child-Pugh-Turcotte Class C), indicating a potential for a much greater degree of accumulation. A multiple-dose study of efavirenz showed no significant effect on efavirenz pharmacokinetics in patients with mild hepatic impairment (Child-Pugh-Turcotte Class A) compared with controls. There were insufficient data to determine whether moderate or severe hepatic impairment (Child-Pugh-Turcotte Class B or C) affects efavirenz pharmacokinetics.</p><p>The pharmacokinetics of emtricitabine have not been studied in non-HBV infected patients with varying degrees of hepatic insufficiency. In general, emtricitabine pharmacokinetics in HBV infected patients were similar to those in healthy subjects and in HIV infected patients.</p><p>A single 245 mg dose of tenofovir disoproxil was administered to non-HIV<strong> </strong>infected patients with varying degrees of hepatic impairment defined according to CPT classification. Tenofovir pharmacokinetics were not substantially altered in subjects with hepatic impairment suggesting that no dose adjustment of tenofovir disoproxil is required in these subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Efavirenz: Non-clinical safety pharmacology studies on efavirenz reveal no special hazard for humans. In repeated-dose toxicity studies, biliary hyperplasia was observed in cynomolgus monkeys given efavirenz for &ge; 1 year at a dose resulting in mean AUC values approximately 2fold greater than those in humans given the recommended dose. The<strong> </strong>biliary hyperplasia<strong> </strong>regressed upon cessation of dosing. Biliary fibrosis has been observed in rats. Non-sustained convulsions were observed in some monkeys receiving efavirenz for &ge; 1 year, at doses yielding plasma AUC values 4- to 13-fold greater than those in humans given the recommended dose. Efavirenz was not mutagenic or clastogenic in conventional genotoxicity assays. Carcinogenicity studies showed an increased incidence of hepatic and pulmonary tumours in female mice, but not in male mice. The mechanism of tumour formation and the potential relevance for humans are not known. Carcinogenicity studies in male mice, male and female rats were negative.</p><p>Reproductive toxicity studies showed increased foetal resorptions in rats. No malformations were observed in foetuses from efavirenz-treated rats and rabbits. However, malformations were observed in 3 of 20 foetuses/newborns from efavirenz-treated cynomolgus monkeys given doses resulting in plasma efavirenz concentrations similar to those seen in humans. Anencephaly and unilateral anophthalmia with secondary enlargement of the tongue were observed in one foetus, microophthalmia was observed in another foetus and cleft palate was observed in a third foetus.&nbsp;</p><p>Emtricitabine: Non-clinical data on emtricitabine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity, carcinogenic potential, and toxicity to reproduction and development.&nbsp;</p><p>Tenofovir disoproxil: Non-clinical safety pharmacology studies on tenofovir disoproxil reveal no special hazard for humans. Findings in repeated-dose toxicity studies in rats, dogs and monkeys at exposure levels greater than or equal to clinical exposure levels and with possible relevance to clinical use include renal and bone toxicity and a decrease in<strong> </strong>serum phosphate concentration. Bone toxicity was diagnosed as osteomalacia (monkeys) and reduced bone mineral density (BMD) (rats and dogs). The bone toxicity in young adult rats and dogs occurred at exposures &ge; 5-fold the exposure in paediatric or adult patients; bone toxicity occurred in juvenile infected monkeys at very high exposures following subcutaneous dosing (&ge; 40-fold the exposure in patients). Findings in the rat and monkey studies indicated that there was a substance-related decrease in intestinal absorption of phosphate with potential secondary reduction in BMD.&nbsp;</p><p>Genotoxicity studies revealed positive results in the in vitro mouse lymphoma assay<strong>, </strong>equivocal results in one of the strains used in the Ames test, and weakly positive results in an UDS<strong> </strong>test in<strong> </strong>primary rat hepatocytes. However, it was negative in an in vivo mouse bone marrow micronucleus assay.</p><p>Oral carcinogenicity studies in rats and mice only revealed a low incidence of duodenal tumours at an extremely high dose in mice. These tumours are unlikely to be of relevance to humans.</p><p>Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. However, tenofovir disoproxil reduced the viability index and weight of pups in peri-postnatal toxicity studies at maternally toxic doses.</p><p>Combination of emtricitabine and tenofovir disoproxil: Genotoxicity and repeated-dose toxicity studies of one month or less with the combination of these two components found no exacerbation of toxicological effects compared to studies with the separate components<strong>.&nbsp; </strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>microcrystalline cellulose, Pregelatinized starch, Croscarmellose sodium, Hydroxy propyl cellulose Sodium lauryl sulfate, Magnesium Stearate Opadry II Pink 85F94172, Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30&rsquo;s Count HDPE container</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab  
Aljameah Street, Malaz quarter,  
Riyadh 11441 
Saudi Arabia 
Tel: +966 11 477 2215 
Manufacture: 
Hetero Lab Unit V, Hyderabad, India  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>